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Abstract
The rapid proliferation of many different engineered nanomaterials (defined as materials designed
and produced to have structural features with at least one dimension of 100 nanometers or less)
presents a dilemma to regulators regarding hazard identification. The International Life Sciences
Institute Research Foundation/Risk Science Institute convened an expert working group to develop
a screening strategy for the hazard identification of engineered nanomaterials. The working group
report presents the elements of a screening strategy rather than a detailed testing protocol. Based
on an evaluation of the limited data currently available, the report presents a broad data gathering
strategy applicable to this early stage in the development of a risk assessment process for
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nanomaterials. Oral, dermal, inhalation, and injection routes of exposure are included recognizing
that, depending on use patterns, exposure to nanomaterials may occur by any of these routes. The
three key elements of the toxicity screening strategy are: Physicochemical Characteristics, In Vitro
Assays (cellular and non-cellular), and In Vivo Assays.
There is a strong likelihood that biological activity of nanoparticles will depend on physicochemical
parameters not routinely considered in toxicity screening studies. Physicochemical properties that
may be important in understanding the toxic effects of test materials include particle size and size
distribution, agglomeration state, shape, crystal structure, chemical composition, surface area,
surface chemistry, surface charge, and porosity.
In vitro techniques allow specific biological and mechanistic pathways to be isolated and tested
under controlled conditions, in ways that are not feasible in in vivo tests. Tests are suggested for
portal-of-entry toxicity for lungs, skin, and the mucosal membranes, and target organ toxicity for
endothelium, blood, spleen, liver, nervous system, heart, and kidney. Non-cellular assessment of
nanoparticle durability, protein interactions, complement activation, and pro-oxidant activity is also
considered.
Tier 1 in vivo assays are proposed for pulmonary, oral, skin and injection exposures, and Tier 2
evaluations for pulmonary exposures are also proposed. Tier 1 evaluations include markers of
inflammation, oxidant stress, and cell proliferation in portal-of-entry and selected remote organs
and tissues. Tier 2 evaluations for pulmonary exposures could include deposition, translocation,
and toxicokinetics and biopersistence studies; effects of multiple exposures; potential effects on the
reproductive system, placenta, and fetus; alternative animal models; and mechanistic studies.
1.0 Introduction
The rapid proliferation of many different engineered
nanomaterials presents a dilemma to regulators regarding
hazard identification. The screening strategy developed by
the International Life Sciences Institute Research Founda-
tion/Risk Science Institute (ILSI RF/RSI) Nanomaterial
Toxicity Screening Working Group is an effort to make a
significant contribution to the initial hazard identification
process for nanomaterial risk assessment.
Engineered nanomaterials are commonly defined as
materials designed and produced to have structural fea-
tures with at least one dimension of 100 nanometers or
less. Such materials typically possess nanostructure-
dependent properties (e.g., chemical, mechanical, electri-
cal, optical, magnetic, biological), which make them
desirable for commercial or medical applications. How-
ever, these same properties potentially may lead to nanos-
tructure-dependent biological activity that differs from
and is not directly predicted by the bulk properties of the
constituent chemicals and compounds. This report out-
lines the elements of a toxicological screening strategy for
nanomaterials as the first step – i.e., hazard identification
– in the risk assessment process. Both in vitro and in vivo
methodologies were considered in the development of
the screening strategy.
Engineered nanomaterials encompass many forms and
are derived from numerous bulk substances. Nanoparti-
cles form a basis for many engineered nanomaterials, and
are currently being produced in a wide variety of types for
a variety of applications; fullerenes (C60 or Bucky Balls),
carbon nanotubes (CNT), metal and metal oxide particles,
polymer nanoparticles and quantum dots are among the
most common.
Engineered nanomaterials are presenting new opportuni-
ties to increase the performance of traditional products,
and to develop unique new products. "The ability to cre-
ate unusual nanostructures such as bundles, sheets, and
tubes holds promise for new and powerful drug delivery
systems, electronic circuits, catalysts, and light-harvesting
materials." [1]
Many current efforts are predominantly focused on using
relatively simple nanostructured materials such as metal
oxide nanoparticles and carbon nanotubes in applica-
tions such as high performance materials, energy storage
and conversion, self-cleaning surface coatings and stain-
resistant textiles. Research into more complex nanomate-
rials is anticipated to lead to applications such as cellular-
level medical diagnostics and treatment and advanced
electronics. However, as nanotechnology blurs tradition-
ally rigid boundaries between scientific disciplines, a
rapid growth in unanticipated applications is to be
expected over the next years and decades.
As new nanotechnology-based materials begin to emerge,
it will be essential to have a framework in place within
which their potential toxicity can be evaluated,Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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particularly as indicators suggest traditional screening
approaches may not be responsive to the nanostructure-
related biological activity of these materials.
Several national and international organizations are cur-
rently developing standard definitions for comment terms
in nanomaterial science including the International Asso-
ciation of Nanotechnology's Nomenclature and Termi-
nology Subcommittee and the American National
Standards Institute Nanotechnology Standards Panel
(ANSI-NSP). The following key definitions are used
throughout this document.
1. Nanoparticle
A particle with at least one dimension smaller than 100
nm including engineered nanoparticles, ambient ultrafine
particles (UFPs) and biological nanoparticles.
2. Engineered/Manufactured Nanoparticle
A particle engineered or manufactured by humans on the
nanoscale with specific physicochemical composition and
structure to exploit properties and functions associated
with its dimensions. Engineered nanoparticles include
particles with a homogeneous composition and structure,
compositionally and structurally heterogeneous particles
(for instance, particles with core-shell structures) and
multi-functional nanoparticles (for instance, 'smart' nan-
oparticles being developed for medical diagnostics and
treatment).
3. Nanomaterial
A material having a physicochemical structure on a scale
greater than typically atomic/ molecular dimensions but
less than 100 nm (nanostructure), which exhibits physi-
cal, chemical and/or biological characteristics associated
with its nanostructure.
4. Nanostructured Particle
A particle with a physicochemical structure on a scale
greater than atomic/molecular dimensions but less than
100 nm, which exhibits physical, chemical and/or biolog-
ical characteristics associated with its nanostructure. A
nanostructured particle may be much larger than 100 nm.
For example, agglomerates of TiO2 nanoparticles that are
significantly larger than 100 nm in diameter may have a
biological activity determined by their nanoscale sub-
structure. Other examples include zeolites, meso-porous
materials and multifunctional particulate probes.
5. Agglomerate/Aggregate
The terms "agglomerate" and "aggregate" are used differ-
ently and even interchangeably in different fields. In the
context of this report, the term "agglomerate" is used
exclusively to describe a collection of particles that are
held together by both weak and strong forces, including
van der Waals and electrostatic forces, and sintered bonds.
In this document, the term is used interchangeably with
'aggregate'. However, the importance of understanding
how the binding forces of an agglomerate affect the dis-
persibility of the component particles under different con-
ditions – in essence how easily the agglomerate de-
agglomerates – is noted.
6. Nanoporous Material
A material with particles that are larger than 100 nm may
have significant structuring on the nanometer size scale,
thereby providing properties based upon this smaller
structuring that may be toxicologically relevant (e.g., dra-
matically increased surface area as compared to the bulk).
Nanoporous materials, such as zeolites, are a significant
class of materials which have porosity in the sub-100 nm
size range but whose primary particles may be large.
2.0 Objectives and Scope
The objective of the ILSI RSI Nanomaterial Toxicity
Screening Working Group, which was convened in Febru-
ary 2005, was to identify the key elements of a toxicity
screening strategy for engineered nanomaterials. The
group considered potential effects of exposure to nano-
materials by inhalation, dermal, oral, and injection
routes; discussed how mechanisms of nanoparticle toxic-
ity may differ from those exhibited by larger particles of
the same chemical; and identified significant data needs
for designing a robust screening strategy.
The elements of a screening strategy for nanomaterials
presented by the Nanomaterial Toxicity Screening Work-
ing Group include an evaluation of the physicochemical
characteristics and dose metrics; acellular assays; in vitro
assays for lung, skin, and mucosal membranes; and in vivo
assays for lung, skin, oral, and injection exposures.
This project was funded by the U.S. Environmental Pro-
tection Agency Office of Pollution Prevention and Toxics
through a cooperative agreement with the ILSI Research
Foundation/Risk Science Institute. It was an outgrowth of
another project under the same cooperative agreement
that proposed strategies for short-term toxicity testing of
fibers [2]. Among the principal conclusions of the latter
project were the importance of the physicochemical char-
acterization of the fibers, the value of subchronic (1–3
month) rat inhalation exposure studies, and the typically
key role in fiber toxicity of biopersistence of inhaled fibers
in the lung and of chronic inflammation leading to cell
proliferation and interstitial fibrosis.
3.0 Literature Survey
The potential for human and ecological toxicity associated
with nanomaterials and ultrafine particles is a growing
area of investigation as more nanomaterials and productsParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
Page 4 of 35
(page number not for citation purposes)
are developed and brought into commercial use. To date,
few nanotoxicology studies have addressed the effects of
nanomaterials in a variety of organisms and environ-
ments. However, the existing research raises some con-
cerns about the safety of nanomaterials and has led to
increased interest in studying the toxicity of nanomateri-
als for use in risk assessment and protection of human
health and the environment. A new field of nanotoxicol-
ogy has been developed to investigate the possibility of
harmful effects due to exposure to nanomaterials [3].
Nanotoxicology also encompasses the proper characteri-
zation of nanomaterials used in toxicity studies. Charac-
terization has been important in differentiating between
naturally occurring forms of nanomaterials, nano-scale
byproducts of natural or chemical processes, and manu-
factured (engineered) nanomaterials. Because of the wide
differences in properties among nanomaterials, each of
these types of nanoparticles can elicit its own unique bio-
logical or ecological responses. As a result, different types
of nanomaterials must be categorized, characterized, and
studied separately, although certain concepts of nanotox-
icology based on the small size, likely apply to all
nanomaterials.
As materials reach the nanoscale, they often no longer dis-
play the same reactivity as the bulk compound. For exam-
ple, even a traditionally inert bulk compound, such as
gold, may elicit a biological response when it is intro-
duced as a nanomaterial [4]. New approaches for testing
and new ways of thinking about current materials are nec-
essary to provide safe workplaces, products, and environ-
ments as the manufacturing of nanomaterials and
products increases and, as a result, exposure to nanomate-
rials increases. The diverse routes of exposure, including
inhalation, dermal uptake, ingestion, and injection, can
present unique toxicological outcomes that vary with the
physicochemical properties of the nanoparticles in
question.
The earliest studies investigating the toxicity of nanoparti-
cles focused on atmospheric exposure of humans and
environmentally relevant species to heterogeneous mix-
tures of environmentally produced ultrafine particulate
matter (having a diameter <100 nm). These studies exam-
ined pulmonary toxicity associated with particulate mat-
ter deposition in the respiratory tract of target organisms
[5-15]. Epidemiological assessments of the effects of
urban air pollution exposure focusing on particulate mat-
ter produced as a byproduct of combustion events, such as
automobile exhaust and other sources of urban air pollu-
tion, showed a link in test populations between morbidity
and mortality and the amount of particulate matter [16-
19]. Some researchers have found an increased risk of
childhood and adult asthma correlated to environmental
exposure to ultrafine particulate matter in urban air [20-
22]. However, other research does not indicate the same
correlation [23-25].
Laboratory-based studies have investigated the effects of a
large range of ultrafine materials through in vivo exposures
using various animal models as well as cell-culture-based
in vitro experiments. To date, animal studies routinely
show an increase in pulmonary inflammation, oxidative
stress, and distal organ involvement upon respiratory
exposure to inhaled or implanted ultrafine particulate
matter [7,11,26-30]. Tissue and cell culture analysis have
also supported the physiological response seen in whole
animal models and yielded data pointing to an increased
incidence of oxidative stress, inflammatory cytokine pro-
duction, and apoptosis in response to exposure to
ultrafine particles [31-37]. These studies have also yielded
information on gene expression and cell signaling path-
ways that are activated in response to exposure to a variety
of ultrafine particle species ranging from carbon-based
combustion products to transition metals. Polytetrafluor-
oethylene fumes in indoor air pollution are nano-sized
particles, highly toxic to rats [38]. They elicit a severe
inflammatory response at low inhaled particle mass con-
centrations, suggestive of an oxidative injury [39-41].
In contrast to the heterogeneous ultrafine materials pro-
duced incidentally by combustion or friction, manufac-
tured nanomaterials can be synthesized in highly
homogenous forms of desired sizes and shapes (e.g.,
spheres, fibers, tubes, rings, planes). Limited research on
manufactured nanomaterials has investigated the interre-
lationship between the size, shape, and dose of a material
and its biological effects, and whether a unique toxicolog-
ical profile may be observed for these different properties
within biological models.
Typically, the biological activity of particles increases as
the particle size decreases. Smaller particles occupy less
volume, resulting in a larger number of particles with a
greater surface area per unit mass and increased potential
for biological interaction [42-46]. Recent studies have
begun to categorize the biological response elicited by var-
ious nanomaterials both in the ecosystem and in mam-
malian systems. Although most current research has
focused on the effect of nanomaterials in mammalian sys-
tems, some recent studies have shown the potential of
nanomaterials to elicit a phytotoxic response in the eco-
system. In the case of alumina nanoparticles, one of the
US market leaders for nano-sized materials, 99.6% pure
nanoparticles with an average particle size of 13 nm were
shown to cause root growth inhibition in five plant spe-
cies [46].
Toxicological studies of fibrous and tubular nanostruc-
tures have shown that at extremely high doses theseParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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materials are associated with fibrotic lung responses and
result in inflammation and an increased risk of carcino-
genesis. Single-walled carbon nanotubes (SWCNT) have
been shown to inhibit the proliferation of kidney cells in
cell culture by inducing cell apoptosis and decreasing cel-
lular adhesive ability. In addition, they cause inflamma-
tion in the lung upon instillation [26,33,47-49]. Multi-
walled carbon nanotubes (MWCNT) are persistent in the
deep lung after inhalation and, once there, are able to
induce both inflammatory and fibrotic reactions [47].
Dermal exposure to MWCNT has been modeled through
cell culture and points to the nanoparticles' ability to
localize within and initiate an irritation response in target
epithelial cells [50]. Proteomic analysis conducted in
human epidermal keratinocytes exposed to MWCNT
showed both increased and decreased expression of many
proteins relative to controls. These protein alterations sug-
gested dysregulation of intermediate filament expression,
cell cycle inhibition, altered vesicular trafficking/exocyto-
sis and membrane scaffold protein down-regulation
[50,51]. In addition, gene expression profiling was con-
ducted on human epidermal keratinocytes exposed to
SWCNT that showed a similar profile to alpha-quartz or
silica. Also, genes not previously associated with these
particulates before from structural protein and cytokine
families were significantly expressed [52]. Dosing kerati-
nocytes and bronchial epithelial cells in vitro with SWCNT
has been shown to result in increases in markers of oxida-
tive stress [50,53,54].
Charge properties and the ability of carbon nanoparticles
to affect the integrity of the blood-brain barrier as well as
exhibit chemical effects within the brain have also been
studied. Nanoparticles can overcome this physical and
electrostatic barrier to the brain. In addition, high concen-
trations of anionic nanoparticles and cationic nanoparti-
cles are capable of disrupting the integrity of the blood-
brain barrier. The brain uptake rates of anionic nanoparti-
cles at lower concentrations were greater than those of
neutral or cationic formulations at the same concentra-
tions. This work suggests that neutral nanoparticles and
low concentration anionic nanoparticles can serve as car-
rier molecules providing chemicals direct access to the
brain and that cationic nanoparticles have an immediate
toxic effect at the blood-brain barrier [55,56].
Tests with uncoated, water soluble, colloidal C60 fuller-
enes have shown that redox-active, lipophilic carbon nan-
oparticles are capable of producing oxidative damage in
the brains of aquatic species [55]. The bactericidal poten-
tial of C60 fullerenes was also observed in these experi-
ments. This property of fullerenes has possible ecological
ramifications and is being explored as a potential source
of new antimicrobial agents [57-59].
Oxidative stress as a common mechanism for cell damage
induced by nano- and ultrafine particles is well docu-
mented; fullerenes are model compounds for producing
superoxide. A wide range of nanomaterial species have
been shown to create reactive oxygen species both in vivo
and in vitro. Species which have been shown to induce free
radical damage include the C60 fullerenes, quantum dots,
and carbon nanotubes [30,60-66]. Nanoparticles of vari-
ous sizes and chemical compositions are able to preferen-
tially localize in mitochondria where they induce major
structural damage and can contribute to oxidative stress
[65].
Quantum dots (QDs) such as CdSe QDs have been intro-
duced as new fluorophores for use in bioimaging. When
conjugated with antibodies, they are used for immunos-
taining due to their bright, photostable fluorescence.
To date, there is not sufficient analysis of the toxicity of
quantum dots in the literature, but some current studies
point to issues of concern when these nanomaterials are
introduced into biological systems. Recently published
research indicates that there is a range of concentrations
where quantum dots used in bioimaging have the poten-
tial to decrease cell viability, or even cause cell death, thus
suggesting that further toxicological evaluation is urgently
needed [67,68]. While it is well known that bulk cad-
mium selenide (CdSe) is cytotoxic, it has been suggested
that CdSe quantum dots are cytocompatible, and safe for
use in whole animal studies. This postulate is based in
part on the use of protecting groups around the CdSe core
of the quantum dot. These coatings have been shown to
be protective, but their long-term stability has not been
evaluated thoroughly. Recent studies exploring the cyto-
toxicity of CdSe-core quantum dots in primary hepato-
cytes as a liver model found that these quantum dots were
acutely toxic under certain conditions. The cytotoxicity
correlates with the liberation of free Cd2+ ions due to dete-
rioration of the CdSe lattice. These data suggest that quan-
tum dots can be rendered nontoxic initially for in vivo use
when appropriately coated. However, the research also
highlights the need to further explore the long-term stabil-
ity of the coatings used, both in vivo and exposed to envi-
ronmental conditions [69].
The range of approaches and methods used to reach con-
clusions regarding the effects of manufactured nanomate-
rials and ultrafine particles has led to different results. This
inconsistency indicates a need for standardized tests in
order to get comparable results in screening nanomateri-
als for potential adverse effects. As the field of nanotoxi-
cology continues to grow, standard toxicology tests will
aid those entering the field and allow for better compari-
sons and conclusions in determining the toxic effects of
nanomaterials.Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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4.0 Elements of a screening strategy for 
nanomaterials
While the nanostructure-dependent properties of many
engineered nanomaterials may place them in the category
of potential hazards, the direct risk they present to human
health will depend on the probability of exposures occur-
ring, and the extent to which materials entering the body
exhibit behavior associated with their nanostructure. Fig-
ure 1[70]; Biokinetics of Nano-sized Particles; While
many uptake and translocation routes have been demon-
strated, others still are hypothetical and need to be inves-
tigated. Largely unknown are translocation rates as well as
accumulation and retention in critical target sites and
their underlying mechanisms. These as well as potential
adverse effects will be largely dependent on physicochem-
ical characteristics of the surface and core of nano-sized
particles. Both qualitative and quantitative changes in
nano-sized particles biokinetics in a disease or compro-
mised organism need also to be considered.
In many cases, nanostructured materials will be compo-
nents of large-scale products such as nano-composites,
surface coatings and electronic circuits, and the potential
for direct exposure will be negligible. However, if
Biokinetics of Nano-sized Particles Figure 1
Biokinetics of Nano-sized Particles. While many uptake and translocation routes have been demonstrated, others still are 
hypothetical and need to be investigated. Largely unknown are translocation rates as well as accumulation and retention in crit-
ical target sites and their underlying mechanisms. These as well as potential adverse effects will be largely dependent on physi-
cochemical characteristics of the surface and core of nano-sized particles. Both qualitative and quantitative changes in nano-
sized particles' biokinetics in a diseased or compromised organism need also to be considered. Reproduced with permission 
from Environmental Health Perspectives.
Exposure Media
Uptake Pathways
Translocation
and Distribution
Excretory Pathways
Air, water, clothes Air Food, water
Skin Respiratory tract
GI tract
Blood
Liver
Lymph
Bone marrow Kidney Spleen
Urine Feces
Deposition
neurons
neurons
Ingestion Inhalation
Other sites
(e.g. muscle, placenta)
(platelets, monocytes,
endothelial cells)
Breast milk
Heart
Sweat/exfoliation
Drug delivery
Injection
Confirmed routes
Potential routes
Lymph
tracheo-
nasal bronchial alveolar
CNS
PNS
neuronsParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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nanostructured materials may enter the body, toxicity
screening strategies are required to ascertain the potential
risk they present.
Nanoparticles are an obvious form of engineered nano-
material presenting a significant exposure potential,
because they can be readily deposited in the lungs or on
the skin, and potentially translocate within the body.
However, agglomerates of nanoparticles from a few hun-
dred nanometers to a few micrometers in diameter may
also be inhaled, ingested or deposited on the skin, and
may have the potential to express toxicity associated with
their nanostructure. Similarly, it is conceivable that
nanostructured particles of a few micrometers in diameter
and below (such as fragments of a nano-composite or a
nanostructured surface coating) may exhibit nanostruc-
ture-dependent biological properties. In each of these
cases, exposure potential exists for materials in air and in
liquid suspensions or slurries.
In this section, three key aspects of toxicity screening strat-
egies are addressed: characterization of nanomaterials, in
vitro screening strategies and in vivo screening strategies
(covering inhalation, dermal, ingestion, and injection
exposure routes). Screening strategies are developed
around nanoparticles, but are relevant to all engineered
nanomaterials that are capable of entering the body
through inhalation, ingestion, dermal penetration, or
injection and expressing biological activity which is asso-
ciated with their nanostructure.
4.1 Physicochemical Characterization
4.1.1 Introduction
Unlike gases, liquids and many solid materials, the desir-
able properties of engineered nanomaterials closely
depend on size, shape and structure (both physically and
chemically) at the nanoscale. Similarly, there is a strong
likelihood that biological activity will depend on physic-
ochemical parameters not usually considered in toxicity
screening studies. Although quantitative toxicity studies
on engineered nanomaterials are still relatively sparse,
published data on fullerenes, single walled carbon nano-
tubes, nanoscale metal oxides such as TiO2 and nanome-
ter-diameter low solubility particles, support the need to
carefully consider how nanomaterials are characterized
when evaluating potential biological activity [62,71-75].
Respirable fibers present perhaps the closest analogy to a
material that is not fully characterized by mass and chem-
ical composition alone. However, the diversity and com-
plexity of nanomaterials suggests that the level of
characterization appropriate to toxicity screening tests will
be commensurately more sophisticated.
Until the mechanistic associations between nanomaterial
characteristics and toxicity are more fully understood, it
will be necessary to ensure that all nanomaterial charac-
teristics that are potentially significant are measured or
can be derived in toxicity screening tests. In particular, in
as far as it is possible; it is desirable to collect sufficient
information to allow retrospective interpretation of toxic-
ity data in the light of new findings. In this context, iden-
tifying a set of characterization criteria for nanomaterial
toxicity screening presents a significant challenge. Clearly,
the ideal of characterizing every possible aspect of a test
material, while laudable, is impractical. In this document,
we have therefore focused on the context under which
characterization takes place and the minimum set of char-
acterization parameters we consider essential within that
context. Essential parameters have been supplemented
with those considered desirable and those considered of
interest but optional within a screening study. The two
overarching characterization contexts discussed are
human exposure studies and in vitro/in vivo studies. In the
case of the latter, we consider material characterization
after administration, characterization at the point of
administration and characterization of the bulk material
as produced or supplied. The relative importance of char-
acterizing dose against different physical metrics during
inhalation exposures is also discussed. Recommendations
are subsequently made on physicochemical characteriza-
tions for nanomaterial toxicity screening tests and charac-
terization methods capable of providing the
recommended information.
4.1.2 Framework for Material Characterization
Material characterization for toxicity screening studies is
most appropriately considered in the context of the stud-
ies being undertaken. Requirements for in vitro and in vivo
screening studies will differ according to the material
delivery route or method. Additionally, understanding
human exposures in the context of developing appropri-
ate screening studies will present a further set of character-
ization requirements. Four screening study contexts are
proposed, and characterization recommendations are
developed within these contexts:
• Human exposure characterization
• Characterization of material following administration
• Characterization of administered material
• Characterization of as-produced or supplied material
Human Exposure Characterization
Where exposure to a specific material is known to occur or
is anticipated, exposure studies are desirable in develop-
ing and selecting appropriate toxicity screening tests. At
present engineered nanomaterials are predominantly at
the research or pre-production stage, and there areParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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relatively few environments where exposures are known
to occur. However, if commercialization of products using
nanomaterials develops as anticipated, the potential for
exposure is likely to increase dramatically over the coming
decade. Therefore, estimates of future use and potential
human exposures should be considered in the develop-
ment of toxicity screening.
Nanomaterial Characterization after Administration
Characterizing delivered nanomaterial after administra-
tion in a test system or model provides the highest quality
of data on dose and material properties that are related to
observed responses, but this is limited by current method-
ological capabilities. Characterization after administra-
tion is particularly advantageous where the possibility of
physicochemical changes in the material before and after
administration exists. Examples of potential changes
include aggregation state, physisorption or chemisorption
of biomolecules and biochemically-induced changes in
surface chemistry. In addition, possible physicochemical
changes as a result of nanomaterial interactions with the
surrounding biological systems such as rapid dissolution
of water- or lipid soluble fractions of the nanomaterial
need to be carefully considered. While characterization
after administration is considered an ideal to work
towards, it is recognized that in many cases, characteriza-
tion at the point of administration will be a more realistic
and feasible option. It is also recognized that in many
cases, characterization at the point of administration will
be essential for the intercomparison of studies, irrespec-
tive of whether characterization after administration is
carried out.
Characterization of Administered Material
Characterization of administered material in toxicity
screening studies is fundamental. This approach addresses
potential physicochemical changes between the bulk
material and the administered material (such as agglom-
eration state) and allows more robust causal associations
between the material and observed responses to be devel-
oped. However, given the strong sensitivity of many nano-
material properties to their local environment, it should
be noted that biologically relevant changes in the physic-
ochemical nature of a nanomaterial between administra-
tion and deposition may have a significant impact on
observed responses in some instances.
Characterization of As-Produced or Supplied Material
Characterization of nanomaterials as-produced or as-sup-
plied represents the most direct approach to obtaining
physicochemical information and may provide useful
baseline data on the material under test. Most engineered
nanomaterials have a functionality based on their physic-
ochemistry. It is therefore likely that information of rele-
vance to toxicity screening studies will be available from
suppliers or producers in many cases. However, due to the
current lack of accepted nanomaterial characterization
standards, it is strongly recommended that wherever pos-
sible, independent characterization of test nanomaterials
be conducted.
Characterization of supplied nanomaterial may not
appropriately represent physicochemical properties of the
material during or following administration. For this rea-
son exclusive reliance on this approach is discouraged,
and is only recommended where characterization of
material during or after administration is clearly not
feasible.
4.1.3 Key Characteristics
Previous studies of asbestos and other fibers have shown
that the dimension, durability and dose (the three D's) of
fibrous particles are key parameters with respect to their
pathogenicity. In general, fibers with a smaller diameter
will penetrate deeper in the lungs. Long fibers (longer
than the diameter of alveolar macrophages) stimulate
macrophages to release inflammatory mediators and will
only be cleared slowly. In addition to fiber length, chem-
ical factors play an important role in fiber durability and
biopersistence; fibers with high alkali or alkali earth oxide
contents and low contents of Al2O3, Fe2O3, TiO2 tend to
have low durability and hence low biopersistence [76].
On the other hand, studies of mineral particles have dem-
onstrated that the toxic and carcinogenic effects are, in
some cases, related to the surface area of inhaled particles
and their surface activity [77,78]. Particle surface charac-
teristics are considered to be key factors in the generation
of free radicals and reactive oxygen species formation and
in the development of fibrosis and cancer by quartz (crys-
tallized silica) [77].
The unusual properties of nanomaterials are predomi-
nantly associated with their nanometer-scale structure,
size and structure-dependent electronic configurations
and an extremely large surface-to-volume ratio relative to
bulk materials. Particles in the nanosize range can deposit
in all regions of the respiratory tract including the distal
lungs. Due to their small size, nanoparticles may pass into
cells directly through the cell membrane or penetrate
between or through cells and translocate to other parts of
the body. Limited data have suggested possible transloca-
tion of inhaled nanoparticles to the nervous system and
other organs/tissues [79-81].
The size of nanoparticles alone may not be the critical fac-
tor determining their toxicity; the overall number and
thus the total surface area may also be important. As a par-
ticle decreases in size, the surface area increases (per unit
mass only; if you normalize to number of particles, the
surface area decreases) and a greater proportion of atoms/Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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molecules are found at the surface compared to those
inside. Thus, nanoparticles have a much larger surface
area per unit mass compared with larger particles. The
increase in the surface-to-volume ratio results in the
increase of the particle surface energy which may render
them more biologically reactive.
Nano-scale materials are known to have various shapes
and structures such as spheres, needles, tubes, plates, etc.
Nanoporous materials are materials with defined pore-
sizes in the nanometer range. The effects of the shape on
the toxicity of nanomaterials are unknown. The shape of
nanomaterials may have effects on the kinetics of deposi-
tion and absorption in the body. The results of a recent in
vitro cytotoxicity study appear to suggest that single-wall
nanotubes are more toxic than multi-wall nanotubes [82].
Chemical composition is another important parameter
for the characterization of nanomaterials, which comprise
nearly all substance classes, e.g., metal/metal oxides, com-
pounds, polymers as well as biomolecules. Some nano-
materials can also be a combination of the above
components in core-shell or other complex structures.
Dependent on the particle surface chemistry, reactive
groups on a particle surface will certainly modify the bio-
logical effects. Under ambient conditions, some nanopar-
ticles can form aggregates or agglomerates. These
agglomerates have various forms, from dendritic structure
to chain or spherical structures. To maintain the character-
istics of nanoparticles, they are often stabilized with coat-
ings or derivative surface to prevent agglomeration. The
properties of nanoparticles can be significantly altered by
surface modification and the distribution of nanoparticles
in the body strongly depends upon the surface character-
istics. Changes of surface properties by coating of nano-
particles to prevent aggregation or agglomeration with
different types and concentrations of surfactants have
been shown to change their body distribution and the
effects on the biological systems significantly [83,84].
Therefore, it is recommended that the following physico-
chemical properties of the test materials should be
characterized:
• Size distribution
• Agglomeration state
• Shape
• Crystal structure
• Chemical composition – including spatially averaged
(bulk) and spatially resolved heterogeneous composition
• Surface area
• Surface chemistry
• Surface charge
• Porosity
4.1.4 Dose Metrics
In any toxicity screening study, careful consideration
should be given to the metric used to quantify dose.
Although response may be associated with a wide range of
physicochemical characteristics, measuring dose against a
physical metric of mass, surface area or particle number
for a well-characterized material will enable quantitative
interpretation of data. Appropriate selection of the dose
metric will depend on the hypothesized parameter most
closely associated with anticipated response or the metric
which may be most accurately measured. It is strongly rec-
ommended that in all cases, sufficient information is col-
lected to enable dose against all three primary physical
metrics to be derived. This may be achieved where the rela-
tionships between nanomaterial mass, surface area and
particle number concentration are known, or where meas-
urements of particle size distribution are made that enable
derivation of all three dose metrics. Where nanomaterials
are administered in a liquid medium, such as in the tech-
nique of intratracheal instillation or pharyngeal aspira-
tion, the nature and amount of material within the
suspension should be fully characterized before delivery
in terms of number, surface area and mass concentration.
Inhalation studies present additional challenges of meas-
uring dose over time, and require both on-line (time
resolved) and off-line analysis.
Off-line mass concentration measurements using filter-
based methods offer continuity with standard inhalation
studies and are recommended as an essential component
of inhalation nanomaterial screening tests. Likewise, on-
line mass concentration measurements are recommended
as an essential component of inhalation studies. Gravi-
metric and/or chemical analysis of filter samples will pro-
vide the most accurate characterization of exposure in
many cases when compared to off-line surface area and
number concentration analyses. With appropriate addi-
tional information, such measurements may be used to
calculate aerosol surface area or number concentration.
However, the diameter cubed relationship between parti-
cle size and mass can lead to large errors when transform-
ing from mass to number concentration if the size
distribution is broad or there are small numbers of exces-
sively large particles present. On-line mass-concentration
measurements using instruments such as the Tapered Ele-
ment Oscillating Microbalance (TEOM®) potentially offer
high precision and good accuracy [85], although they areParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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susceptible to errors where the sampled aerosol contains
volatile components. On-line photometric mass
concentration methods are generally good for monitoring
the temporal stability of aerosol and providing a real-time
indication of mass exposure, although they are relatively
insensitive to particles smaller than approximately 0.5 µm
in diameter [86]. However, in general more appropriate
methods should be used for providing real-time measure-
ments of number and surface-area exposure [85,87-89].
Aerosol size distribution measurements enable reasona-
bly good calculation of exposure against all three physical
metrics, if parameters such as particle shape and density
are known. Off-line size distribution measurement meth-
ods such as Transmission Electron Microscopy (TEM)
analysis offer detailed information on this distribution
but are extremely time consuming, and frequently limited
by the collection techniques and, in the case of TEM anal-
ysis, inference of 3-dimensional structure from 2-dimen-
sional images. On-line size measurement techniques such
as Differential Mobility Analysis [90] are capable of meas-
uring aerosol size distribution with a time resolution of
tens of seconds. Aerosol number concentration between
given particle diameters is easily derived from aerosol size
distribution measurements, although interpretation of
such data in terms of mass or surface-area dose requires
additional information on particle characteristics such as
shape and density. It is recommended that for each nano-
particle type, size distribution measurement techniques
be validated against TEM analysis.
Off-line surface area characterization is possible using
isothermal gas-adsorption, although techniques suited to
filter samples need to be employed. There is also some
possibility that the surface area of the collected material
will differ from that of the airborne material due to com-
paction and surface occlusion. However, the extent to
which this may occur is not well understood. Published
studies have shown a good correlation between off-line
surface area measurement and biological response [91],
suggesting that errors associated with collection and sub-
sequent analysis can be small. This holds particularly for
insoluble particles; ideally surface area measurements
would be required on the insoluble core of a nanomate-
rial after its water-and/or lipid soluble compounds have
been dissolved from the particle surface. Aerosol diffusion
charging has been shown to provide a measure of surface
area on-line where the charging rate is low [89], and a
small number of aerosol diffusion chargers are commer-
cially available. These devices have been shown to meas-
ure aerosol surface area well for particles smaller than 100
nm in diameter [87]. At larger diameters, measured sur-
face area progressively underestimates aerosol surface
area. In particular, the surface area of porous particle
structures as well as that of highly aggregated particles will
generally not be determined. Data have been published
on a particular aerosol diffusion charger indicating that it
provides a measure of aerosol surface area dose in the
lungs, as opposed to aerosol surface area exposure [92].
While on-line aerosol surface area measurements are
desirable during inhalation exposure studies, uncertain-
ties associated with current techniques suggest caution
when interpreting such measurements.
Number concentration may be measured on-line with
relative ease using instruments such as Condensation Par-
ticle Counters [88]. Although it is not clear how biologi-
cally relevant number concentration is as a dose metric,
the ease with which such measurements are made and
their value in tracking temporal changes in exposure lead
to their being recommended as essential in inhalation
studies.
Table 1 summarizes recommendations for measuring
exposure during inhalation studies.
4.1.5 Characterization Prioritization
In developing recommendations on material characteriza-
tions for nanomaterial toxicity screening studies, three
specific factors have been taken into consideration: the
context within which a material is being evaluated, the
importance of measuring a specific parameter within that
context, and the feasibility of measuring the parameter
within a specific context. Recommendations on off-line
material characterizations for nanomaterial toxicity
screening studies are presented in Table 2.
Table 1: Recommendations for measuring exposure during 
inhalation studies
Metric Measurement 
Recommendation
Mass – off-line E (coupled with on-line)
Mass – on-line E
Size distribution – off line E
Size distribution – on line E/D
Surface area – off line O
Surface area – on line O
Number – off line N
Number – on line E
E: These measurements are considered to be essential.
D: These measurements are considered to provide valuable 
information, but are not recommended as essential due to constraints 
associated with complexity, cost and availability.
O: These measurements are considered to provide valuable but non-
essential exposure information.
N: These measurements are not considered to be of significant value 
to inhalation studies.Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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In addition, recommendations have been made on
recording information on nanomaterial production, prep-
aration, storage, heterogeneity, and agglomeration state.
To enable retrospective interpretation of toxicity data and
replication of tests, it is strongly recommended that all
information on the production and processing of nano-
materials be recorded. Fully documenting storage time
and conditions (including temperature, humidity, expo-
sure to light and atmosphere composition) is essential, as
physicochemical changes may take place over time. If pos-
sible, the physicochemical stability of samples over time
should be demonstrated. Where a test material is a heter-
ogeneous mixture of different components, information
is required on the relative abundance of the different com-
ponents, and whether associations in the bulk material
are maintained in the administered material, or whether
different components are preferentially administered with
specific delivery mechanisms.
The agglomeration state of a nanomaterial during and fol-
lowing administration may have a significant impact on
its biological activity. Agglomeration state at different
structure scales should be characterized, including pri-
mary (primary particles), secondary (primary particle
agglomerates and self-assembled structures) and tertiary
(assemblies of secondary structures) scales. Ideally,
agglomeration state in the biological environment follow-
ing administration should be evaluated. If possible, some
insight into the binding forces within agglomerates (e.g.
relatively weak van der Waals forces or relatively strong
sintered bonds) should be obtained. Material
agglomeration or de-agglomeration in different liquid
media should also be investigated where possible.
Characterization of material as administered is recom-
mended as the highest priority, supplemented by charac-
terization after in vitro or in vivo administration where
possible, and followed in order of preference by character-
ization of the material as produced or supplied. Recom-
mended characterizations in Table 2 reflect both this
hierarchy and the feasibility of making measurements
within the respective contexts.
4.1.6 Analysis Methods
Many analytical techniques, both established and devel-
opmental, are available for characterizing the nanomate-
rial properties listed in Table 2. Table 3 lists some of the
more widely available techniques and relates them to the
nanomaterial characteristics of interest to toxicity screen-
ing studies. Techniques have been categorized with
Table 2: Recommendations on material characterization
Characterization (Off-line) Human exposure Toxicity Screening Studies
Supplied 
material
Administered 
material
Material in 
vivo/in vitro
Size distribution (primary particles) E (Combine with agglomeration state) E D D
Shape E E O O
Surface area D E D O
Composition E E O O
Surface chemistry D E D D/O
Surface contamination D N D N
Surface charge – suspension/solution O E E O
Surface charge – powder (use bio fluid surrogate) O E N O
Crystal structure O E O O
Particle physicochemical structure E E D D
Agglomeration state E N E D
Porosity D D N N
Method of production E E -- --
Preparation process -- -- E --
Heterogeneity D E E D
Prior storage of material E E E --
Concentration E -- E D
E: These characterizations are considered to be essential.
D: These characterizations are considered to provide valuable information, but are not recommended as essential due to constraints associated 
with complexity, cost and availability.
O: These characterizations are considered to provide valuable but non-essential information.
N: These characterizations are not considered to be of significant value to screening studies.P
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Table 3: Applicability of a range of analytical techniques to providing specific physicochemical information on engineered nanomaterials, in the context of toxicity screening 
studies
Analytical technique
Transmission 
Electron 
Microscopy 
(TEM)
Scanning 
Electron 
Microscopy 
(SEM)
X-Ray 
Diffraction 
(XRD)
X-ray Photon 
Spectroscopy 
(XPS)
Auger 
Spectroscopy 
(AES)
Secondary 
Ion Mass 
Spectrometry 
(SIMS)
Scanning 
Probe 
Microscopy
Dynamic 
Light 
Scattering 
(DLS)
Zeta 
potential
Size Exclusion 
Chromatography
Analytical 
Ultracentrifugation
Differential 
Mobility 
Analysis 
(DMA)
Isothermal 
Adsorption 
(e.g. BET)
Spectroscopic 
techniques 
(UV vis, IR, 
Raman, NMR)
Elemental 
analysis (eg 
ICP-MS/AA 
etc)
Physicochemical 
Characteristic
Size 
distribution 
(primary 
particles)
▲● ● ● ● ● ● ●
Shape ▲● ●
Surface area ●    ●
Composition ●● ● ▲ ●▲
Surface 
chemistry
●● ● 
Surface 
contamination
●●
Surface charge 
– suspension/
solution
▲
Surface charge 
– powder (use 
bio fluid 
surrogate)
▲
Crystal 
structure
●  ▲
Particle 
physicochemic
al structure
▲●
Agglomeration 
state
▲● ● ●
Porosity  ●●
Heterogeneity ▲● 
Other applicable techniques are available that have not been listed.
▲ Highly applicable
●  Capable of providing information in some cases
 Capable of providing information in some cases, with validation from more accurate/applicable techniques
 Capable of providing qualitative or semi-quantitative information
9 9
9
9 9 9 9
9 9 9
9
9 9 9 9
9
9Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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respect to their applicability to specific material character-
istics. In general, the table is self-explanatory, and further
information on each technique can be obtained from a
wide range of sources. A number of techniques are only
suitable for materials in certain forms, or specific classes
of materials. For instance, while Transmission Electron
Microscopy is capable of providing a wealth of informa-
tion on nanoparticles and is considered a gold standard
for evaluating particle size distribution and shape, dry (or
in the case of cryo-TEM, frozen liquid-encapsulated) well-
dispersed samples that are sufficiently robust to withstand
high vacuums are required. Similarly, techniques such as
Infrared (IR) spectroscopy are particularly sensitive to sur-
face organic compounds, but are less useful for quantify-
ing inorganic surface chemistry. In a number of cases, a
complex technique such as TEM can be used to validate a
characterization method that is more practical to use on a
routine basis.
Given the wide range of analytical techniques available in
many disciplines associated with nanotechnology, multi-
disciplinary collaborations with research and analysis
groups offering state of the art nanomaterial characteriza-
tion capabilities are strongly recommended when carrying
out nanomaterial toxicity screening studies.
4.1.7 Research Gaps
1. The development of viable in vivo nanomaterial
(including nanoparticles) detection techniques.
2. The development and production of inexpensive real-
time monitoring instruments and methods for aerosol
mass concentration (low concentrations, nanoscale parti-
cles), surface area concentration and size distribution.
3. The development of standardized, well characterized
nanomaterial samples.
4. The development of radio-labeled nanomaterial sam-
ples, and samples that can be tracked and detected
through neutron-activation.
5. The development of more advanced surface chemistry
characterization techniques, in particular techniques
capable of detecting and speciating biological molecules
on the surface of nanoparticles and nanomaterials.
6. The development of electron microscopy techniques for
biologically-relevant nanoscale analysis.
4.1.8 Recommendations
1. All nanomaterial physicochemical characteristics that
are potentially significant should be measured or be deriv-
able in toxicity screening tests.
2. Characterization of nanomaterial as administered is
strongly recommended, supplemented by characteriza-
tion following administration where it is technically feasi-
ble and practicable. Characterization of the bulk material
as-produced or supplied to the exclusion of the above is
not recommended, except where more appropriate meas-
urements are not feasible.
3. It is recommended that independent characterizations
of nanomaterials (beyond information provided by pro-
ducers and suppliers) are carried out where possible.
4. It is recommended that the following physicochemical
properties of nanomaterials should be characterized in
the context of toxicity screening tests: Particle size distri-
bution, agglomeration state, particle shape, crystal struc-
ture, chemical composition (bulk and spatial), surface
area, surface chemistry, surface charge, and porosity.
5. It is recommended that in all cases, sufficient informa-
tion be collected to enable derivation of the delivered
dose against all three primary physical metrics (number,
surface area and mass concentration).
6. Off-line mass concentration measurements using filter-
based methods are recommended as an essential compo-
nent of inhalation nanomaterial screening tests. In addi-
tion, off-line measurement of aerosol size distribution is
recommended.
7. On-line mass concentration and number measure-
ments are recommended as an essential component of
inhalation studies.
8. Multidisciplinary collaborations between research and
analysis groups offering state of the art nanomaterial char-
acterization capabilities are strongly recommended.
9. It is recommended that information on nanomaterial
production, preparation, storage, heterogeneity and
agglomeration state be recorded for all nanomaterial tox-
icity screening studies.
10. It is recommended that nanomaterial preparation
methods are fully documented, including the selection of
appropriate dispersion media, methods of dispersion in
the medium and agglomeration state within the medium.
Specific preparation techniques are not recommended, as
these will depend on the material and test protocols being
used. However, caution is advised when using ultrasonic
agitation to disperse materials, as at high energies the
method may be sufficiently aggressive to alter the material
characteristics (see section 4.3.1.1).Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
Page 14 of 35
(page number not for citation purposes)
4.2 In vitro Testing Methods
4.2.1 Introduction
Before considering the application of specific in vitro test-
ing methods to the assessment of the toxicity of nanoma-
terials, there are several generic issues that should be
noted.
1) Advantages and disadvantages In general in vitro tech-
niques are seen as an important adjunct to in vivo studies.
These studies allow specific biological pathways to be
tested under controlled conditions, as well as isolation of
pathways that is not feasible in vivo; e.g., it is difficult to
discriminate in vivo whether complement activation has a
role in any pro-inflammatory effects of particles. The com-
plement system can be isolated in vitro, and its potential
role investigated. There are, of course, well-documented
problems with in vitro approaches, including lack of vali-
dation against in vivo adverse effects, dosimetry mismatch,
over-simplicity, non-involvement of the complete inflam-
matory response, etc.
2) Control particles It is important, in view of the above,
that adequate positive and negative control particles are
included in all experiments. This at least allows the test
particle to be bench-marked against particles of known
toxicity. These can include standard crystalline silica
(quartz; e.g, Min-U-Sil or DQ12) as a known cytotoxic
particle and fine TiO2 as an inert particle.
3) Expression of dose Toxicity and other responses should
be expressed in relation to a range of dose metrics depend-
ing on the material and the dose metric data that are avail-
able (see Section 4.1).
4) Adsorption of proteins by nanoparticles The large sur-
face area of nanoparticles means that they are capable of
adsorbing proteins. Nanoparticles of various types have
been reported to adsorb key proteins such as albumin
[93], fibronectin and TGF-β [94]. This may confound end-
points that rely on the measurement of a protein as the
protein may be produced but may also remove from the
supernatant onto the nanoparticle surface by adsorption,
providing a false-negative.
The in vitro tests that are presented will be divided into
portal of entry toxicity and target organ toxicity. The
potential target cells and associated appropriate end-
points will be described. Finally, research gaps and recom-
mendations will be identified.
4.2.2 Portals of Entry
4.2.2.1 Lungs
The lungs represent a potential target for any airborne par-
ticles, and many in vitro models for the lung exist. Particles
deposit on the airway or alveolar epithelium and encoun-
ter mucus or epithelial lining fluid. They may then interact
with macrophages, which may result in their clearance, or
they may enter the interstitium where they may make con-
tact with fibroblasts and endothelial cells or cells of the
immune system.
The Epithelium
The epithelium is the first barrier that confronts particles
that deposit in either the conducting airways or the alveo-
lar region. Therefore, both bronchial and alveolar epithe-
lial cells should be considered as target cells for in vitro
studies. Endpoints for detecting nanoparticle effects could
include toxicity measurements, such as LDH release, for
necrosis or various cytokine expression (IL-8, MCP-1 etc),
[91,95] and activation of inflammation-related transcrip-
tion factors such as NF-κB and AP-1[96,97]. Oxidative
and nitrosative stress are dominant mechanistic hypothe-
ses for cell damage and activation caused by pathogenic
particles. These can be monitored by measuring oxidative
stress using dichlorofluorescein [98] or oxidized glutath-
ione as endpoints [99] and nitrosated proteins as a meas-
ure of active nitrogen species [100]. Responses to particle-
induced oxidative/nitrosative stress can include up-regu-
lation of anti-oxidant genes [101] such as superoxide dis-
mutase and glutathione peroxidase, and so these can also
be measured. Proliferative effects of nanoparticles can be
assessed using a variety of assays including bromo-deoxy-
uridine incorporation [102].
If cancer is an endpoint that is under consideration, then
direct measures of genotoxicity can be quantified by
methods that include COMET assay and 8-hydroxy-deox-
yguanosine measurement [103,104]. The translocation of
nanoparticles across the epithelium could be an impor-
tant discriminator of harmfulness and, although there are
few publications specifically addressing transfer of parti-
cles across the epithelium in vitro, these should be devel-
oped and could contribute to understanding the factors
that regulate translocation.
Macrophages
Macrophages play a key role in the cellular response to
particles that deposit in the lungs. Macrophages could be
affected by nanoparticles in various ways that can be stud-
ied in vitro through a variety of assays. Cellular cytotoxicity
could be measured using conventional methods, such as
lactate dehydrogenase release. Macrophage activation
occurs following phagocytosis of a number of pathogenic
particles leading to release of cytokines (tumour necrosis
factor alpha (TNFα), interleukin-6 (IL-6) etc) and nuclear
transfer of inflammation-related transcription factors
nuclear factor kappa B (NF-κB) and activator protein
1(AP-1). Macrophages undergo an oxidative burst (OB)
on phagocytosis of particles [105] and the extent of this in
response to nanoparticles could be investigated. NitricParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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oxide (NO) may also be produced, in response to particles
[106] and in the presence of superoxide radical peroxyni-
trite, a highly toxic species, can be produced [107]. If the
OB or NO production is exaggerated, there could be
'bystander' injury to epithelial cells whilst diminished
OB/NO production could mean impaired microbicidal
activity that allows infection. Another key macrophage
function reported to be impaired by nanoparticles is
phagocytosis, [108] and so the effect of test nanoparticles
on this function could be considered. The cytoskeleton is
key to normal cell functioning and could be targeted by
nanoparticles and so could be investigated.
Endothelial cells
Although these are found in the lungs, they are considered
a part of the cardiovascular system and are dealt with
below.
Fibroblasts
Fibroblasts are found in the interstitium and are liable to
be affected by any particle that gains access to this site. At
least two important modes of response could be activated
by nanoparticle/fibroblast interactions and both modes
constitute relevant endpoints for in vitro testing: 1) Pro-
inflammatory effects, measured by cytokine/chemokine
gene expression (TNFα; etc); or 2) fibrogenic responses
activated either by direct stimulation of fibroblast growth
or extra-cellular matrix secretion by the nanoparticle, or
by autocrine stimulation following nanoparticle-stimu-
lated release from the fibroblasts of growth factors such as
transforming growth factor beta and platelet-derived
growth factor.
The Immune System
Immunopathological effects could be envisaged if parti-
cles interact with lymphocytes, or as a consequence of
their predilection for entering the interstitium, they mod-
ulate dendritic cell function. The effects of nanoparticles
on immunological functions including antigen presenta-
tion by macrophages and dendritic cells and the subse-
quent effects on immune responses in vitro are relevant
endpoints and appropriate tests should be designed.
Co-Cultures
In addition to monocultures of lung cells, co-cultures such
as epithelial cells/macrophages or epithelial cells/
endothelial cells may more closely represent the in vivo sit-
uation, and so such studies are encouraged.
Lung Slices
Methodology to culture whole lung tissue slices is availa-
ble, such that multiple pulmonary cell types can be
exposed in vitro in the same configuration as they occur in
vivo.
Cell Lines vs. Freshly-Derived Cells
If possible, freshly-derived primary cells should be used.
Where cell lines are used, these should preferably not be
cancer cells. Where cancer cells are used, the endpoint
response under study should be carefully compared to
non-cancer cells to ensure that, for that endpoint, the fact
that the cell is a cancer cell does not greatly modify the
response compared to a non-cancer cell.
Whole Heart-Lung Preparation
The Langendorff heart-lung preparation may provide the
opportunity to study the behavior of nanoparticles under
highly controlled conditions. In this model the exsan-
guinated heart and lungs are maintained by perfusion and
so transport between the lungs and the vascular space can
be studied in the absence of blood [109].
4.2.2.2 Skin
Skin or the integument is the largest organ of the body and
is unique because it is a potential route for exposure to
nanoparticles during their manufacture and also provides
an environment within the avascular epidermis where
particles could potentially lodge and not be susceptible to
removal by phagocytosis [110]. What are the toxicological
consequences of "dirty" nanoparticles (catalyst residue)
becoming lodged in the epidermis? In fact, it is this rela-
tive biological isolation in the lipid domains of the epi-
dermis that has allowed for the delivery of drugs to the
skin using lipid nanoparticles and liposomes. Larger par-
ticles of zinc and titanium oxide used in topical skin-care
products have been shown to be able to penetrate the stra-
tum corneum barrier of rabbit skin with highest absorp-
tion occurring from water and oily vehicles [111]. This
could also apply to manufactured nanoparticles. Can nan-
oparticles gain access to the epidermis after topical expo-
sure, the first step in a toxicological reaction? Exposure to
metallic nanoparticles, whose physical properties would
allow them to catalyze a number of biomolecular interac-
tions, potentially could produce adverse toxicological
effects. More information is required regarding the effi-
ciency of decontamination of nanoparticles from skin
since solubilization and dilution, the two hallmarks of
post-exposure decontamination, might be less efficacious
for these solid structures.
Research should address the effects of dermal and sys-
temic exposure to a number of types of nanoparticles in
the skin. The skin is a primary route of potential exposure
to toxicants, including novel nanoparticles. However,
there is no information on whether particles are absorbed
across the stratum corneum barrier or whether systemi-
cally administered particles can accumulate in dermal tis-
sue. Nanoparticles may traverse through the stratum
corneum layers at varying rates due to particle size orParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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become sequestered within the epidermis to increase their
exposure time to viable epidermal keratinocytes.
Nanomaterials are difficult to obtain in large quantities;
therefore, it is best to conduct in vitro tests to estimate in
vivo starting doses for toxicity testing [112]. At least three
or four concentrations with controls should be used in all
in vitro systems. These data would provide a preliminary,
but relevant, assessment of both systemic exposure after
topical administration as well as cutaneous hazard after
both topical and systemic exposure, two essential compo-
nents of any risk assessment.
Cell Culture
Human epidermal keratinocyte (HEK) monolayers can be
affected by nanoparticle interactions. It has already been
shown that changes in biomarkers of viability and toxicity
can occur with exposure to multi-wall carbon nanotubes
[50]. Cytotoxicity endpoints should be evaluated: 1) cell
viability-metabolic markers such as mitochondrial reduc-
tion of tetrazolium salts into insoluble dye (MTT), 2)
decreased cell viability-membrane markers like neutral
red uptake into cell lysosomes, trypan blue exclusion and
cell attachment/cell detachment, and 3) pro-inflamma-
tory cytokine affects measured by TNFα, IL-8, IL-6, IL-10,
or IL-1β. Genomics and proteomics assays could be used
to explore the mechanism behind the toxicity. However,
caution must be taken when using carbon black or any
other material as a control because complications may
occur. Carbon can adsorb the viability dyes, such as neu-
tral red, and interfere with the absorption spectra. False
positives will occur. The type of carbon black used is
extremely important. For instance, ultrafine carbon black
has been utilized in inhalation studies but dosing in cell
culture gives different results, especially when conducting
viability and cytokine assays.
Three dimensional skin cell cultures are also available
commercially. They have shown to be able to predict irri-
tation but may significantly overestimate absorption or
penetration [113-116]. Assays listed above can be used
but may not be applicable with nanomaterials due to
adsorption.
Flow-through Diffusion Cell Studies
Diffusion cell system consists of flow-through diffusion
blocks each containing multiple Teflon cells perfused by a
constant temperature circulator through a Silastic oxygen-
ator, an automatic fraction collector, and a desiccant. Cir-
cular fresh skin from pigs (pig skin mimics human skin
and eliminates the extreme variability seen with random
source human skin) or humans are placed epidermal –
side up in Teflon flow-through diffusion cell. Compound
containing nanoparticles is dosed on the epidermal side
whilst the dermal side in each cell is bathed with receptor
fluid at a set flow rate. The perfusate is collected at defined
intervals up to 24 hrs and nanoparticles flux in the per-
fusate can be assessed by radioactivity counting, fluores-
cence, or UV detection. The skin surface can then be
swabbed to remove non-absorbed surface particles and
then tape stripped to remove a stratum corneum sample
to assess nanoparticle penetration into this outermost epi-
dermal layer. Serial sectioning of the skin can also be car-
ried out [117,118].
Isolated Perfused Porcine Skin Flap (IPPSF)
The isolated perfused porcine skin flap (IPPSF) would be
an ideal model to study the absorption and toxicity of
nanomaterials. The IPPSF has an intact functional micro-
circulation, a viable epidermis and dermis and can be well
controlled. A single-pedicle, axial pattern tubed skin flap
is obtained from the abdomen of pigs following surgical
creation of the flap perfused primarily by the caudal
superficial epigastric artery and its associated paired venae
commitantes. The IPPSF is transferred to the perfusion
apparatus that is a custom designed temperature and
humidity-regulated chamber. Nanomaterials can be topi-
cally dosed to the skin surface and perfusate samples col-
lected over an eight hour period and assessed for
nanoparticle flux [119-121].
Other acute toxicity in vitro assays are available but are
used to test corrosives (rat transcutaneous electrical resist-
ance (TER), commercially available EPISKIN, Epiderm
and Corrositex) and irritation (EPISKIN, and Epiderm).
However, the major traditional endpoint for skin toxicity
is using the cell viability assay MTT reduction that has
been shown to be unpredictable with nanomaterials due
to marker interactions with nanoparticles.
4.2.2.3 Mucosa
Mucosa is the moist tissue that lines particular organs and
body cavities throughout the body, including the nasal
cavity, oral cavity, lungs, vagina and gastrointestinal tract.
Potentially one of the most important portals of entry for
nanoparticle exposure (excluding the nasal cavity and
lung, which has been detailed above) is the gastrointesti-
nal tract. Either accidental or intentional exposure via oral
administration to the GI tract can lead to significant expo-
sures. Efficient uptake of nanoparticles via the GI tract has
been well documented in oral feeding studies and gavage
studies using particles ranging from 10 nm to 500 nm
[122-124]. In these studies nanoparticles translocated
through the mucosal lining and epithelial barrier of the
intestine and were associated with the GALT (gastroinstet-
inal associated lymphatic tissue) and circulatory system
within as little as 60 minutes time [125].
Intestinal epithelium can be studied using a variety of
methods including immortalized cell-lines and tissueParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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constructs. An example of immortalized cell-lines used to
study the uptake of materials across the intestinal epithe-
lial barrier include Caco cells, which have been used in
many pharmaceutical studies to determine intestinal per-
meability [126].
These assays could be adapted for use in in vitro transloca-
tion rate studies or for developing a mechanistic under-
standing of the translocation process. IEC-6 and IEC-18
cell lines have been used extensively in mechanistic stud-
ies of the intestinal epithelial lining as well and may rep-
resent useful tools for nanoparticle research [127-129].
These cells have been used to measure the activation of
various signal pathways after toxicant exposure, as well as
cytokine and ROS/RNS release [130,131].
Dependent upon the specific application, vaginal and
oral-lining exposure may be possible although it is
unlikely that these, in general, would represent significant
portal of entry exposure routes. However, there are a vari-
ety of cell-lines and tissue constructs or models available
for study of translocation and impact of nanoparticle
exposure through these routes [132-134].
4.2.3 Cellular Assays
Study of target organs distal to the site of deposition pre-
supposes that there is translocation and redistribution of
nanoparticles away from the portals of entry in the lungs,
skin or gut. As discussed above, potential target organs
include blood, endothelium, neural tissue, heart, kidney,
liver, and spleen.
4.2.3.1 Endothelium
The endothelium is represented by a thin layer of cells lin-
ing the vasculature throughout the body. It has been dem-
onstrated that ultrafine particles or nanoparticles may
have a wide range of effects on the endothelium. In vitro
cultures may be useful in elucidating mechanistic infor-
mation about transport across the alveolo-capillary or
blood-brain barrier and on endothelial cell effects. Cul-
tured endothelial cells are well suited to determining the
effects nanoparticles may have on RNS production which
has been demonstrated to play a significant role in the
homeostasis of the vasculature [135-137].
4.2.3.2 Blood
In vitro studies using fractionated blood products (isolated
red blood cells, platelets, leukocytes, or serum with com-
plement) can be utilized in evaluating the effect on circu-
lating blood. Activation of platelets, red blood cell
interactions, production of ROS/RNS, cytokine/chemok-
ine release from leukocytes, and complement activation
are relevant endpoints to evaluate for nanoparticles. It has
been demonstrated that nanoparticles have the ability to
enter the circulatory system once translocation from site
of entry has occurred [138,139].
4.2.3.3 Spleen
The spleen is a major site of immune processing and lym-
phoid maturation, and accumulation of particles in the
spleen may have consequences for immune responses and
immunopathology. Spleen cells can be isolated and stud-
ied for the effects of nanoparticles in vitro. Endpoints
could include antigen processing and immune responsiv-
ity in vitro, markers of lymphoid cell differentiation, and
functional aspects such as dendritic cell function and lym-
phocyte proliferation.
4.2.3.4 Liver
The liver is a complex organ and is structurally and func-
tionally heterogeneous. The liver is the major site for
biotransformation and defense against foreign materials
and xenobiotics. It is an integral structure having two sep-
arate blood supplies, many different cell types, and many
different functions. Liver injury, due to nanomaterials,
may be characterized based on histologic lesions, such as
inflammation or necrosis. Injury to the liver may also be
characterized at the molecular level. Some of the most
common mechanisms of hepatocellular injury are via the
cytochrome P450 metabolic pathways. The liver can
excrete materials into the bile; therefore, the biliary system
may be exposed as well. In vivo there are reports that a vari-
ety of different toxins cause hepatocellular injury by a
range of different mechanisms such as cytochrome P450
activation, alcohol dehydrogenase activation, membrane
lipid peroxidation, protein synthesis inhibition, disrup-
tion of calcium homeostasis, and activation of pro-apop-
totic receptor enzymes. Every effort should be made to use
human derived cells for in vitro assays, because these stud-
ies could be used to predict toxicity in humans. However,
there is a considerable human variability in enzyme
function.
Primary Human Hepatocytes
Primary human hepatocyte cultures are available com-
mercially with well-characterized metabolic profiles and a
full complement of metabolizing enzymes. Availability of
human cells is limited due to the increase in demand for
liver transplantations.
Isolated Perfused Liver
This complicated model system would be suitable for the
study of nanomaterials, because it is the closest model
that mimics in vivo and would allow for a detailed charac-
terization of particle distribution within the organ.
Liver Slices
Modern techniques of precision slicing have allowed liver
slices to become a good model, because it retains the nor-Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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mal tissue organization which may be particularly critical
for nanoparticle studies.
Collagen Sandwich Cultures
In this model system, the structural and functional integ-
rity is retained for several days. The bile canaliculi are well
preserved, and release of the enzymes alanine ami-
notransferase and aspartate aminotransferase can be
evaluated.
In general, using these in vitro systems, hepatic metabo-
lism can be studied using isolated hepatocytes and cell
lines and evaluated for changes in CYP450. Microsomes
may be used in screening nanomaterials for metabolism
using LC/MS to identify metabolite formation. Subcellu-
lar fractions, liver slices and whole liver homogenates may
be used to evaluate liver function and toxicity. To study
the effects of nanomaterials on hepatic function specific
endpoints, such as enzyme systems, mitochondrial func-
tion, albumin synthesis, cell detachment, gene and / or
protein expression, and membrane damage should be
considered. Mechanistically distinct endpoints could be
utilized, such as cell morphology, viability, membrane
damage, alamar blue metabolism, ATP content, covalent
protein binding, peroxisomal proliferation, and GSH con-
tent. Other biomarker identifications, such as transcrip-
tion and proteomic profiling should be studied. However,
biomarkers may have limitations because immortalized
cell lines are genotypically and phenotypically different
from the organ itself. Also, hepatocyte cell cultures repre-
sent a single cell system and will only provide information
on events that directly affect the cell itself. Some of these
test systems may be able to predict the toxicity of nanoma-
terials as long as the assumptions and limitations are real-
ized [140,141].
4.2.3.5 Nervous System
Central Nervous System
In vitro systems to study the effects of particles on the nerv-
ous system could include culture of neurons and addition
of nanoparticles to determine effects on neuronal func-
tion. Endpoints could include ROS/RNS production,
apoptosis, metabolic status, effects on the action potential
and ion regulation in general. Microglial cells are a type of
macrophage found in the brain, and they may be involved
in handling any nanoparticle that gets to the brain. The
responses of microglial cells to nanoparticles should be
studied along the lines of those described for macro-
phages in the lung section. Other cells that could be stud-
ied for effects of nanoparticles are astrocytes, glial cells
that have a number of important roles that influence the
behavior of neurons, and oligodendrocytes which provide
support to axons by producing the myelin sheath, which
insulates the axons.
Peripheral Nervous System
The skin and the other portals of entry and target organs
will have a nerve supply and the skin for example, has sen-
sory nerves that are present near the surface of the body.
Nanoparticles have the potential to gain access to these
nerves and be transported or affect them in a number of
ways. This could be studied by using neuron culture of
peripheral nerves and studying the effect of nanoparticles
for various relevant endpoints (e.g., dorsal root ganglion
neurons). In the autonomic nervous system both sympa-
thetic and para-sympathetic neurons can be cultured, and
effects of nanoparticles on their viability, metabolism,
electrical activity and ionic homeostasis could be studied.
4.2.3.6 Heart
Cardiac function could be altered by nanoparticles that
find their way into the heart muscle from the microcircu-
lation. Cardiomyocytes can be cultured and effects on
their general viability, ionic homeostasis and metabolism
could be ascertained. Additionally, cardiomyocytes beat
with regular rhythm in vitro, and the effects on this could
be measured and any effects examined as to mechanism.
4.2.3.7 Kidney
The kidney is a major filtering system to eliminate toxi-
cants from the bloodstream and it has been demonstrated
that nanoparticles can be excreted via the kidney. Whether
there are adverse effects of nanoparticles on the kidneys is
unknown but this can be evaluated using in vitro tech-
niques. Permeability assays used in pharmaceutical stud-
ies can be evaluated for use in measuring translocation
and penetration through the renal tubules. Effects on the
epithelial tubules and vasculature can be evaluated with
existing cell culture techniques. A variety of endpoints can
be evaluated, including signal transduction response, oxi-
dative stress, cellular viability, ion channel flux, modula-
tion in the release of growth factors and proteinases as
important indicators to renal homeostasis. Several mod-
els exist that may be useful to investigate nanoparticle-
kidney interactions including renal tissue slices to evalu-
ate translocation, oxidative stress, signal transduction
responses and toxicity [142,143]. Immortalized cell-lines
are an inexpensive alternative to kidney slice models and
may provide mechanistic information on the cytotoxicity
of nanomaterials. Cells derived from isolated glomeruli,
distal tubule/ collecting ducts, proximal tubule or proxi-
mal nephrons have been well characterized and are com-
mercially available [144,145]. An example is the use of
HEK-293 cells (human embryonic kidney cells) to evalu-
ate cytotoxicity of chemicals [146]. MDKK cells and LLC-
PK1 cells have been used extensively in in vitro mechanis-
tic studies and can be utilized to evaluate effects of nano-
particles [147,148].Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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4.2.4 Non-Cellular Assays
Durability
The ability of a particle to persist contributes to its ability
to accumulate as dose. In fiber toxicology, there are well-
documented dynamic and static protocols for assessing
this property of durability in vitro, using Gambles bal-
anced salt solution [149]. These fiber protocols could be
modified to allow measurement of durability of nanopar-
ticles in vitro.
Complement Activation
The complement system is a protein cascade that has
evolved to detect foreign, mostly microbial, surfaces. It is,
however, activated by asbestos [150] and by carbon nan-
oparticles [151]. Their high surface per unit mass and
surface activity may mean that other types of nanoparti-
cles might be potent at activating the complement system.
This might modify the response by opsonising the parti-
cles (C3b) or causing inflammation by the production of
anaphylatoxin (C5a). Studies on the ability of nanoparti-
cles to activate the complement system are therefore
warranted.
Adsorptive Properties
The large surface area of nanoparticles means that they
can adsorb proteins [152,153]. Adsorption of different
proteins might occur with different nanoparticle surfaces,
and this could modify how they are handled by macro-
phages and other cells. This could therefore be a focus of
study.
Free Radical Production
Most, probably all, pathogenic particles generate free rad-
icals in cell-free systems, and this ability to cause oxidative
stress contributes to their ability to initiate inflammation,
and cause cell injury and genotoxicity [95,154-157]. The
free radicals can arise as a consequence of stable radicals
at the particulate surface (quartz) [158], redox cycling of
ionic transition metal via the Fenton reaction (e.g. weld-
ing fume), [159] or by unknown surface mechanisms
(nanoparticle carbon black) [160]. The ability of particles
to generate free radicals can be assessed by a range of
assays, including plasmid DNA scission [161], electron
paramagnetic spin resonance, [162] and 8-OH-dG pro-
duction in 'naked' DNA or a DCFD assay for in vitro ROS
production [163].
Computational Toxicology
In addition to establishing screening methods mentioned
above, efforts to assess risk associated with engineered
nanomaterials or other environmental stressors should
include a collection of new technologies called computa-
tional toxicology. Computational toxicology is defined as
the application of mathematical and computer models
and molecular biology approaches to improve prioritiza-
tion of data requirements and risk assessments for envi-
ronmental protection.
This approach involves four areas:
- computational chemistry which refers to physical-chem-
ical-mathematical modeling at the molecular level and
includes topics such as quantum chemistry, force fields,
molecular mechanics, molecular simulations, molecular
modeling, molecular design, and cheminformatics;
- molecular biology which allows for the characterization
of genetic constituency and the application of wide cover-
age technologies, such as genomics, proteomics, and
metabonomics, to provide the key indicators of cellular
and organismal response to stressor input;
- computational biology or bioinformatics, which
involves the development of molecular biology databases
and the analysis of the data;
- systems biology which refers to the application of math-
ematical modeling and reasoning to the understanding of
biological systems and the explanation of biological
phenomena.
Computational toxicology is designed to increase the
capacity to prioritize, screen, and evaluate materials by
enhancing the ability to predict their toxicity. In addition
to the "omics," quantitative structure-activity relation-
ships (QSARs) developed in physical organic chemistry
should be evaluated as to whether they can aid in predict-
ing the structure-property relationship of nanomaterials.
These multidisciplinary models could then be considered
in a source-to-outcome continuum from environmental
release through entire concentration, exposure concentra-
tion, target organelles, early biological effects, and adverse
outcome.
While finding the relationship between structure and tox-
icity of nanomaterials using computational toxicology is
likely a long time away, it is well to keep these models in
mind while developing screening methods and to use cur-
rent methods to validate and inform their development.
4.2.5 Research Gaps
There is a paucity of data on the effects of nanoparticles on
these different target cells and their respective endpoints
in vitro. We therefore identify an urgent research need to
obtain more information about nanoparticles in all of
these systems. We do, however, identify some pressing
needs and these include:
1. In vitro assays need to be used to determine important
parameters that drive the toxicity and translocation poten-Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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tial of nanoparticles e.g. size, surface area, surface reactiv-
ity, etc.
2. Decisions have to be made regarding the most appro-
priate and useful in vitro endpoints and their relative util-
ity and importance (e.g. translocation, generation of ROS,
cytokine release, cytotoxicity). A ranking of these in vitro
assays in order of relevance and utility should be
attempted.
3. In vitro data should be used to develop a paradigm for
nanoparticle toxicity that predicts the toxicity based on
measurement of in vitro parameters; when mature, this
paradigm could be critically tested in vivo.
Table 4: Available in vitro systems for portal of entry testing
Portal of Entry Cell/Tissue Type Effect Endpoint Research Gap
Lung Epithelium Toxicity Trypan blue, LDH, apoptosis
Inflammation Gene expression, oxidative stress, 
signal transduction pathways
Translocation Transfer of nanoparticles across 
membranes
Translocation process
Carcinogenesis Genotoxicity, comet assay, 8OHdG, 
hprt assay, proliferation assay
Macrophages Toxicity Trypan blue, LDH, apoptosis
Chemotaxis Chemotaxis assay Recognition/Activation/
Phagocytosis Process
Phagocytosis Particle uptake into cells, cytoskeletal 
staining
Inflammation Gene expression, oxidative stress, 
signal transduction pathways
Additional markers?
Immune Cells Immune response Cytokine profile, adjuvant effects Additional markers?
Endothelium Inflammation Adhesion molecules, oxidative stress Additional markers?
Coagulation Von Willebrand factor, tissue factor
Fibroblasts Inflammation Oxidative stress, cytokine profile, 
gene expression profile
Fibrosis Collagen synthesis, cell proliferation
Lung slices Inflammation Oxidative stress, signal transduction 
pathway, immuno-histopathology
Translocation Particles across membranes Translocation process
Fibrosis Collagen synthesis
Skin Cell systems (e.g. HEK) Cytotoxicity Inflammation Cell viability – MTT, neutral red, 
Cytokine profile
Flow-through diffusion 
systems
Absorption
Isolated Skin Flap Model Absorption, Cytotoxicity, 
Inflammation
Glucose utilization, any other 
markers depending on end points 
(cytokine profiles, histopath, etc.)
Mucosa Intestinal epithelium (GI 
tract)
Cytotoxicity Cell viability – MTT, neutral red, 
trypan blue Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway
Translocation Permeability assays
GALT Inflammation Cytokine profile, oxidative stress
Immune response Adjuvant effects Additional markers?
Buccal epithelium (oral 
cavitiy)
Cytotoxicity Cell viability – MTT, neutral red, 
trypan blue Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway
Translocation Permeability assays
Vaginal epithelium 
(reproductive system)
Cytotoxicity Cell viability – MTT, neutral red, 
trypan blue Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway
Translocation Permeability assaysParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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4. Toxicokinetic data should be used to select the target
cells and systems that are appropriate and to select plausi-
ble dose levels to use in the in vitro assays.
5. The effect of nanoparticle form (e.g. singlet particles or
aggregates, use of surfactant) should be determined and
Table 5: Available in vitro systems for potential target organs
Target Organ Cell/Tissue Type Effect Endpoint Research Gap
Endothelium Endothelial cells (e.g. HUV-
EC-C)
Cytotoxicity Cell viability – MTT, neutral red, 
trypan blue Apoptosis
Homeostasis Oxidative stress, gene expression 
profile
Additional markers?
Translocation Permeability assays
Blood Red blood cells, platelets, 
bone marrow 
(megakaryocytes)
Inflammation/Immune 
response
Platelet activation
Cytokine/chemokine release 
from leukocytes
Oxidative stress
Complement activation
RBC/particle interactions Markers?
Liver Hepatocytes Toxicity Cell viability – MTT, neutral red, 
trypan blue Apoptosis
Kupffer cells Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway, gene 
expression
Coagulation Von Willebrand factor, tissue 
factor
Isolated perfused liver 
slices
Translocation, distribution Histopathology Translocation process
Liver slices Toxicity studies Cytotoxicity, P450 assay, ATP 
assays, GSH content
Additional markers? 
Genomics, Proteomics?
Collagen sandwich cultures Toxicity studies Cytotoxicity, P450 assay, ATP 
assays, GSH content
Additional markers? 
Genomics, Proteomics?
Spleen Lymphocytes Immune response Cytokine profile
Central and peripheral 
nervous system
Neuronal cells Toxicity Cytotoxicity – Trypan blue, LDH 
Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway, gene 
expression
Translocation Gene expression, microscopic 
examination
Astroglial, Microglial cells Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway, gene 
expression
Heart Cardiomyocytes Toxicity Cytotoxicity – Trypan blue, LDH 
Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway, gene 
expression
Function Beat – rhythm testing
Kidney Cell (e.g. HK-2, MDCK, 
LCC-PK1)
Toxicity Cytotoxicity – Trypan blue, LDH 
Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway, gene 
expression
Translocation Permeability assays Additional markers?
Kidney slices Toxicity Cytotoxicity – Trypan blue, LDH 
Apoptosis
Inflammation Cytokine profile, oxidative stress, 
signal transduction pathway, gene 
expression
Translocation Permeability assays Additional markers?Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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the nanoparticle dose should be characterised as much as
possible, e.g. regarding surface area, metals, etc.
6. There is a pressing need to prepare and choose appro-
priate benchmark materials for in vitro testing.
7. How do we interpret in vitro results without appropriate
mechanistic information from in vivo models?
4.2.6 Recommendations
Table 4 presents available in vitro systems for portal of
entry testing. Table 5 presents available in vitro systems for
other potential target organs.
1. In vitro tests are recommended as they provide a rapid
and relatively inexpensive way to assess the potential tox-
icity of nanoparticles; there are, however, well-docu-
mented drawbacks of the in vitro assays such as their
relative simplicity and the high doses commonly utilized.
2. We recommend that "benchmark" particle controls be
utilized in all studies such as crystalline silica and respira-
ble TiO2.
3. Non-cellular tests including nanoparticle durability,
complement activation, adsorption and free radical pro-
duction can all yield valuable data on potential harmful-
ness of nanoparticles; computational toxicology may also
make a contribution.
4. Attention should be given to the potential confounding
effect of adsorption of proteins or assay constituents onto
the nanoparticles surface.
5. Various cell-based systems are available with varying
benefits and drawbacks, including single cell cultures of
cell lines and freshly-derived cells, co-cultures, organ cul-
tures (e.g. tracheal explants) and heart-lung preparations.
6. The lung is a key target organ and so lung epithelial
cells, macrophages, immune cells and fibroblasts repre-
sent key cells for nanoparticle effects with specific regard
to inflammation, immunopathology, fibrosis, genotoxic-
ity, microbial defense and clearance.
7. Skin represents a target for nanoparticles, especially
from nanoparticles in cosmetics and a number of in vitro
test systems are recommended including keratinocyte cul-
ture, Flow-through Diffusion Cell, and Isolated Perfused
Porcine Skin Flap (IPPSF).
8. Mucosa, the moist tissue that lines the nasal cavity, oral
cavity, lungs, vagina and gastrointestinal tract also repre-
sents a potential target for nanoparticles and various in
vitro  systems are available for testing and should be
utilized.
9. The tendency of nanoparticles to gain access to the vas-
culature means that endothelium and components of the
blood are potential targets of nanoparticles and these can
be studied in vitro and we urge that this pathway receive
special attention.
10. The spleen, kidney, heart and liver will be target
organs for bloodborne nanoparticles and we advise that a
number of in vitro test systems are available to model
effects in these organs.
11. Transfer of nanoparticles to the brain and interactions
with the autonomic nervous system in the lungs have
been reported and we strongly recommend that in vitro
models be utilized to study the impact of nanoparticles in
these important neural cells.
4.3 In vivo Assays
The following section details a two tier approach to in vivo
assays. In Vivo assays are presented for pulmonary, oral,
dermal and injection exposures. Tier 1 evaluations are pre-
sented for all routes of exposure and Tier 2 evaluations are
presented for pulmonary exposures. Tier 1 Evaluations
include markers of damage, oxidant stress, and cell prolif-
eration. The Tier 2 evaluation for pulmonary exposures
includes deposition, translocation, and biopersistence
studies; effects of multiple exposures; potential effects on
the reproductive system, placenta, and fetus; alternative
animal models; and mechanistic studies. The section con-
cludes with identification of research gaps and a summary
of principal recommendations related to in vivo testing of
nanomaterials.
4.3.1 Pulmonary Exposure – Tier 1
Currently little information is available regarding air-
borne levels of nanomaterials generated during produc-
tion and processing or quantities which may be
aerosolized into the environment. However, due to their
small size, aerosolization of respirable nanomaterials is
likely, either as singlet or as aggregated particles and expo-
sure by the inhalation route is a concern [48]. The follow-
ing is a template which is recommended for the
evaluation of possible adverse effects on the lung and
other organ systems of pulmonary exposure to nanomate-
rials. A critical step in in vivo testing of nanomaterials is
the characterization of the test material as described in
Section 4.1.
4.3.1.1 Exposure Method
Inhalation
Inhalation is the preferred method of exposure of the res-
piratory tract for hazard identification and to obtain dose-Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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response data. Physicochemical characterization of the
generated aerosol is essential. Of particular interest is
information regarding the particle size distribution of the
aerosolized nanomaterial, i.e., singlet nanoparticles vs.
aggregates of primary particles. The generated aerosol
must be well controlled for particle size and concentra-
tion, and attempts should be made to reproduce human
exposure conditions for a specific airborne nanomaterial.
A critical barrier to conducting inhalation studies with
nanomaterials is that the amount of material is often lim-
ited. Intratracheal inhalation uses less material than
whole body or nose-only inhalation exposures, but still
requires more than may be available. Under such con-
straints, pulmonary exposure by intratracheal instillation,
pharyngeal or laryngeal aspiration is acceptable for hazard
identification. It has to be kept in mind that the upper res-
piratory tract will not be targeted.
Intratracheal Instillation
Intratracheal instillation of nanomaterial suspended in an
appropriate vehicle is considered an acceptable method
for pulmonary exposure to evaluate the relative toxicity of
the test material [164]. Efforts should be made to disag-
gregate the nanomaterial suspended in vehicle. Nanopar-
ticles vary significantly in their dispersibility; given the
lack of other general techniques for disaggregating such
particles, vortexing plus sonication is recommended.
However, both probe and bath sonication may generate
significant localized heat and pressure, disrupting surface
coatings which were intentionally used to impart specific
characteristic to the nanoparticles. Where sonication must
be used, bath sonication is recommended. In all cases, the
specific preparation technique (duration and power of
sonication) should be reported. The characterization of
the suspended particles should define the exposure mate-
rial with respect to vehicle and degree of vortexing and
sonication of the sample. Suspension of nanomaterial in
a serum or surfactant-containing vehicle is sometimes
employed to assist disaggregation of the nanoparticles.
However, because these substances would adhere to the
particle surface, the effect of such surface coatings on the
biological activity of the particle is an issue which must be
evaluated.
Pharyngeal and Laryngeal Aspiration
Pharyngeal aspiration has been shown to be an effective
exposure method which results in a relatively even distri-
bution of particles throughout the lungs [165]. A concern
with the pharyngeal aspiration technique for pulmonary
exposure is the unintentional aspiration of food particles
from the oral cavity during this procedure. Therefore, food
should be withheld the night before the aspiration expo-
sure. Furthermore, a naïve group should be added in addi-
tion to the vehicle control to evaluate any pulmonary
effects of aspiration alone [165]. As an alternative to pha-
ryngeal aspiration exposure and to avoid contamination
with materials from the oral cavity, laryngeal aspiration
may be used, particularly in rats.
4.3.1.2 Design
Animal Model
Currently, a large database exists using rats or mice to eval-
uate the pulmonary toxicity of particles. Therefore, for
comparability to other toxicology studies, the use of the
rat or mouse model is preferred. However, other animal
models may be preferred to evaluate specific endpoints
and would be acceptable.
Gender
At this time, there is no information concerning gender
specific pulmonary sensitivity to nanomaterials. There-
fore, there is no recommendation as to a preferred gender
for these studies.
Dosimetry
Since mass may not be the proper dose metric for compar-
ing the toxicity of fine vs. ultrafine particles [166,167],
characterization of the test material should also include
surface area per mass and particle number per mass. For
practical purposes, dose could be monitored as mass
delivered/animal or mass inhaled/animal and then be
converted easily to a surface area or particle number dose
as necessary, provided the correlation between these three
particle parameters is available.
Benchmark Material
To place any pulmonary response to exposure to a given
nanomaterial in perspective, results should be compared
to those for particles of well-defined toxicity. Such bench-
mark materials could include nano-sized TiO2, carbon
black, or crystalline silica. These benchmark materials
should be characterized for surface area and particle
number per mass, as well as for particle size and with
respect to chemical purity and crystallinity to allow com-
parisons to be made using a variety of dose metrics.
Exposure Concentration
It is recommended that a minimum of three exposure lev-
els be used. Information regarding the actual anticipated
exposure levels in humans would be useful in determin-
ing the exposure concentration range to be evaluated.
However, such information for nanoparticles is often
lacking. In all cases, similar exposure concentrations of
the test and benchmark materials should be used, and the
various dose metrics discussed above should be consid-
ered when choosing the exposures for the benchmark and
test materials. It is recommended that the highest concen-
tration chosen should exhibit toxicity with the benchmark
material.Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
Page 24 of 35
(page number not for citation purposes)
Exposure Duration
For intratracheal instillation or pharyngeal aspiration, a
single exposure to the nanomaterial is sufficient for Tier 1
studies. Caveat: consider high dose and bolus effect! For
inhalation, a two week exposure is recommended,
although shorter exposures, perhaps at higher concentra-
tions, should be done if this mimics human exposures.
Pulmonary Parameters
Pulmonary responses should be monitored 24 hours to
28 days post-exposure. A suggested time course could be
24 hrs, 1 week and 28 days post-exposure.
4.3.1.3 Pulmonary Endpoints
Inhalation Studies
The degree/intensity and duration of pulmonary inflam-
mation and cytotoxic effects following nanoparticle expo-
sures are important endpoints for assessing the toxicity of
a test nanoparticle.
1. Bronchoalveolar lavage (BAL) damage markers – BAL
profile. This method samples the cells and fluid from the
bronchoalveolar space and allows the assessment of
inflammation by quantification of cell numbers and types
and components of the fluid phase. In addition, consider-
able extra information can be gained by various ex vivo
manipulations of the BAL cells, e.g., gene expression,
phagocytic potential, etc. Other BAL damage markers
include BAL lactate dehydrogenase levels (as a measure of
cytotoxicity), BAL protein levels (increases in BAL fluid
protein concentrations generally are consistent with
enhanced permeability of vascular proteins into the alve-
olar regions, indicating a breakdown in the integrity of the
alveolar-capillary barrier), and BAL alkaline phosphatase
levels (as a measure of Type 2 alveolar epithelial cell tox-
icity). Methodologies for cell counts, differentials, and
pulmonary biomarkers in lavaged fluids have previously
been described [168,169].
2. Oxidative stress markers – ROS/RNS. Reactive oxygen
and nitrogen species have been implicated in DNA dam-
age and induction of inflammatory cytokines and growth
factors. Acellular BAL fluid levels of gluthathione, total
antioxidants, or nitrate/nitrite (a measure of nitric oxide
production), lipid peroxidation of lung tissue, or ex vivo
measurement of ROS/RNS from BAL cells can be
employed to monitor oxidant generation and oxidant
stress. Methodologies for oxidative stress markers have
been described [170,171].
3. Histopathology – Description of the general effects of
treatments on the lungs should include endpoints such as
presence of dust-laden macrophages, cellular infiltrates
and hyperplastic changes in the epithelium. It is recom-
mended that the entire respiratory tract be evaluated for
adverse pathological effects. This would include the upper
respiratory tract – the nose, larynx and upper airways; the
lower respiratory tract and lymph nodes; and the pleural
region. Histopathological observations in a Tier 1 process
would focus primarily on inflammatory responses and the
development of fibrosis. Fibrosis can be determined in
lung tissue by specific staining of collagen in histopatho-
logical slides, or by qualitative and quantitative
histopathology.
4. Cell proliferation – Increased cell division plays a key
role in pathological responses and can be determined in
epithelial or mesothelial cells by uptake of labeled nucle-
otide precursors, such as tritiated thymidine or BrdU. Rec-
ommended experiments are designed to measure the
effects of particle exposures on airway and lung parenchy-
mal cell turnover in rats following exposures. Groups of
particulate-exposed rats and corresponding controls can
either be pulsed or implanted subcutaneously with min-
ipumps containing 5-bromo-2'deoxyuridine (BrdU)
dissolved in a sodium bicarbonate buffer solution. Meth-
odologies for cell proliferation studies have previously
been described [168,169]. An alternative method to BrDU
staining is the PCNA staining method. Proliferating cell
nuclear antigen (PCNA) is a nuclear protein associated
with cell proliferation and has been used to discriminate
via immunohistochemistry proliferating cells in numer-
ous tumor types including those found in the lung [172-
174].
Intratracheal Instillation or Pharyngeal/Laryngeal Aspiration Studies
As discussed above, inhalation is the most physiologically
relevant and therefore preferred method of pulmonary
exposure for hazard identification and to obtain dose-
response data. However, both intratracheal instillation of
nanomaterials suspended in an appropriate vehicle and
pharyngeal or laryngeal aspiration (with appropriate cave-
ats) are considered to be acceptable methods for pulmo-
nary exposure to evaluate the relative toxicity of the test
material. Similar to studies using aerosol exposures, the
following pulmonary endpoints should be evaluated in a
Tier 1 testing strategy approach for assessing lung hazards
to nanoparticles:
1. BAL damage markers
2. Oxidative stress markers
3. Histopathology
4. Cell proliferation
4.3.1.4 Other Organ Endpoints
Exposure to nanoparticles via the respiratory tract includes
a high probability of translocation to other organs and tis-Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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sues – depending on nanoparticle size and surface chem-
istry. Although translocation rates may be very low,
localization at sensitive sub-cellular sites (e.g., mitochon-
dria) could result in adverse responses directly induced by
the nanoparticle. Alternatively, or in addition, potential
oxidative stress and inflammatory responses elicited by
nanoparticles in the respiratory tract may result in the
release of mediators which can lead to indirect secondary
effects in extra-pulmonary organ systems. Thus, it is essen-
tial to include an evaluation of potential effects in remote
organs and tissues, such as liver, spleen, bone marrow,
heart, kidney, and CNS, in the Tier 1 evaluation.
Histopathological examination of extra-pulmonary tis-
sues should be mandatory; however, this alone may only
show significant effects following longer-term or very high
exposures. Therefore, consideration should also be given
to determining organ-specific endpoints, such as acute
phase proteins and coagulation factors, for effects on the
cardiovascular system, immune response assays for effects
on the spleen, and immunohistochemical staining for
dopaminergic neurons in brain sections to evaluate neu-
rogenic effects. Additional functional assays (e.g., meas-
urement of heart rate variability) may be considered, but
since they require specific equipment and expertise, these
are not mandatory for Tier 1 studies.
4.3.2 Pulmonary Exposure – Tier 2
Research results showing that nanoparticles can translo-
cate from the portal of entry, the respiratory tract, via dif-
ferent pathways to other organs/tissues makes them
uniquely different from larger-sized particles in that they
may induce direct adverse responses in remote organs. In
particular, such responses may be initiated through the
interaction of nanoparticles with sub-cellular structures
following endocytosis by different target cells. For this rea-
son, special attention needs to be given to recognizing
such effects, which in the healthy organism are probably
very subtle initially, even not detectable, but could have
serious consequences in a compromised organism or a
compromised organ. Examples are effects of anthropo-
genic ultrafine particles in asthmatics, in people with car-
diovascular diseases, in the elderly and very young.
Complementary Tier 2 studies can be used to obtain more
data for hazard identification as an initial step for risk
assessment. Tier 2 studies will provide additional infor-
mation to either characterize further effects seen in Tier 1
studies or to obtain new data using specific models of sus-
ceptibility. Ideally, studies should be performed using
inhalation exposures as a first choice, in particular if a
positive response was seen in Tier 1 studies when intratra-
cheal instillation or pharyngeal/laryngeal aspiration was
used. If insufficient amounts of material are available,
multiple low dose (1–10 µg/kg body weight) exposures of
the respiratory tract using the above-mentioned non-
inhalation methods can be applied, i.e., dosing once or
twice/week for 4 weeks with 2–3 months follow-up.
4.3.2.1 Animal Models
The absence of an effect of nanoparticles in a normal ani-
mal model does not imply that there will be no effect in a
model which exhibits enhanced susceptibility. Increased
susceptibility can be due to a number of factors, including
age, disease, altered organ function, genetic polymor-
phism. Respective animal models include exposures of
senescent, transgenic and knockout animals and animals
with compromised organ systems (e.g., hypertension; dia-
betes models; immuno-compromised, infectivity mod-
els). In general, susceptibility models include
compromised functions of the respiratory tract, CNS, car-
diovascular system (dysfunction of endothelial cells,
platelets), bone marrow, and/or kidney. It is essential that
the models used are relevant to the human disease state
and that a respective animal model has been validated in
the peer-reviewed literature. In addition to obtaining
information for identifying nanoparticle hazards, Tier 2
studies will also provide data on underlying mechanisms
which can be used in concert with the mechanistic in vitro
studies.
4.3.2.2 Multiple Exposures
As indicated above and under Tier 1 studies, repeated
inhalation exposures are the first choice for realistic dos-
ing. Information about the physicochemical nature of air-
borne nanoparticles at the workplace, or anticipated
exposure of the general public (consumer), is essential to
mimic the same for animal exposures. Issues include: are
the nanoparticles aggregated or singlets; what is the diam-
eter in the airborne state; what is known about other
chemical characteristics (see discussion in this document,
Section 4.1.)? Generation and monitoring of airborne
nanoparticles for inhalation exposures requires special
equipment and expertise. As an alternative to inhalation,
intratracheal instillation, oropharyngeal or laryngeal aspi-
ration can be used. However, unless the nanoparticles are
coated and made "soluble" in physiological solutions,
artifacts due to aggregation may occur when using these
non-inhalation methods. In addition, the upper respira-
tory tract is circumvented by the non-inhalation methods,
thereby eliminating potential neuronal nanoparticle
translocation to the CNS. To address this concern, one
could expose the animal to nanoparticles by nasal instil-
lation. Techniques for tracking the uptake of nanoparti-
cles by sensory neurons would be similar to those
discussed in the section concerning deposition,
translocation, and biopersistence (Section 4.3.2.3). Fur-
thermore, the impact of coating for purposes of "solubi-
lizing" the nanoparticles has to be carefully considered in
cases where anticipated human exposure is to theParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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uncoated material, since cellular uptake, translocation
and effects will be affected by the surface coating.
Daily repeated inhalation exposures over four weeks are
suggested for the Tier 2 studies, with an up to 3-month
post-exposure observation period, including interim post-
exposure sacrifice days. With respect to the non-inhala-
tion methods of exposure, dosing can occur 1–2 times/
week over a 4-week period, followed by the post-exposure
observation period. Special attention needs to be given to
the selection of exposure concentrations (inhalation) and
doses (instillation, aspiration). Knowledge about antici-
pated human exposure will be extremely valuable, and
use of predictive particle deposition models (e.g., MPPD
model) can be used to determine realistic exposure
concentrations/doses.
The Tier 2 studies are aimed at obtaining additional infor-
mation with respect to the biokinetics of the nanomateri-
als following exposure of the respiratory tract (see below,
"Deposition, translocation and biopersistence studies"),
the stability of nanoparticles in the organ system (e.g., in
vivo change of surface chemistry, bioavailability of core
material), and the potential acute and sub-acute effects in
the mammalian organism, including genomic and pro-
teomic evaluation. Other endpoints are the same as listed
under Tier 1 studies for the respiratory tract.
4.3.2.3 Deposition, Translocation and Biopersistence Studies
Exposure to airborne nanoparticles via  the inhalation
route leads to deposition in the various compartments of
the respiratory tract according to probabilities dependent
on three important parameter groups: aerodynamic and
thermodynamic nanoparticle properties, breathing pat-
tern, and the three-dimensional geometry and structure of
the respiratory tract. Deposition probability of nanoparti-
cles below a thermodynamic diameter of 500 nm
increases with decreasing size because of the increasing
diffusion velocity leading to an increased deposition in
the small airways and the alveoli, in particular. Below 20
nm, the location of deposition of nanoparticles changes
to the upper respiratory tract because of their even higher
diffusion velocity [175]. Currently existing computer
codes provide a first estimate of deposition probabilities
in the various regions of the respiratory tract which may
require modification if there are indications that nanopar-
ticles may undergo changes of their aero- and/or thermo-
dynamic properties not being considered in those codes
[176,177].
Once deposited, insoluble nanoparticles undergo clear-
ance mechanisms specific to the region of the respiratory
tract; i.e., at all regions nanoparticles will interact with
proteins of the epithelial lining fluid potentially forming
complexes which are likely to affect their subsequent met-
abolic fate and biokinetics [178]. On the epithelium of
conducting airways, mucociliary clearance provides a
rapid transport, to the larynx for further transport into the
gastro-intestinal tract and excretion. Note, however, that
there also occurs long-term retention in human airways
for a fraction of nanoparticles which increases with the
decreasing size of nanoparticles giving rise to cellular
uptake. On the epithelium of the alveolar region there is
no rapid transport so that phagocytosis by free phagocytes
can occur with subsequent slow clearance to the larynx,
but because of the limited capability of macrophages to
recognize nanoparticles, endocytotic processes and trans-
cellular transport by other cells like epithelial type I + II
cells, become prominent together with para-cellular trans-
port mechanisms across tight junctions under inflamed
conditions [179,180]. These mechanisms result in trans-
location of nanoparticles into the interstitium, lymphatic
drainage and possible translocation across endothelial
cells into capillaries. This access to the blood circulation
provides accumulation and possible adverse reactions in
secondary target organs such as the cardiovascular system,
liver, spleen, bone marrow, central nervous system, endo-
crine organs and interaction with endothelial cells, plate-
lets and immuno-competent cells in the circulation.
Besides the direct effects of translocated nanoparticles on
secondary organs, indirect effects may occur as well trig-
gered by interactions of nanoparticles at their site of reten-
tion in the respiratory tract with adjacent biological
systems like cells, fluids, proteins and extracellular matrix.
Subsequent cell activation can lead to release of cytokines
and other mediators which subsequently diffuse into the
circulation to induce adverse responses in secondary tar-
get organs. Because the underlying mechanisms of nano-
particle translocation and accumulation or mediator
response in secondary target organs are not fully under-
stood, the determination of nanoparticle kinetics should
be a high priority.
The scenario described above relates to biopersistent nan-
oparticles which maintain their particulate state; however,
nanoparticles even when they may be insoluble in water
may not persist as a solid particle in cells and body fluids
but may fully or partially (e.g., surface coating) disinte-
grate/dissolve, so that eventually a biopersistent core with
different particle properties/toxicities is retained. Because
of the high diversity of emerging nanoparticles, studies of
their biopersistence should be regarded of high priority.
Methodologies for such biopersistence studies include:
• Radio-labeled or fluorescently or magnetically tagged moni-
toring in lungs and various organs
Radio-labeling of nanoparticles specifically with a radio-
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particle matrix is the gold standard for studying transloca-
tion kinetics allowing for time-efficient, extremely high
sensitivity and specificity measurements, particularly
when they aim to account for a balance of the entire dis-
tribution in the body and in excretions [79,181]. Also flu-
orescent or magnetic labeling provides a powerful means
of high sensitivity and specificity to determine translo-
cated fractions in various target organs [181,182]. Extreme
care should be taken; however, to assure that any label
stays firmly with the nanoparticles, otherwise the results
will be severely flawed. Also, evidence is required that the
process of labeling does not modify the nanoparticle in its
function and its surface since surface is the predominant
interacting substrate with biological systems.
• If impossible to tag: EM to monitor deposition and fate
Labeling of nanoparticles will not be possible in every
case. In this event tracking of nanoparticles by electron
microscopy may be a suitable alternative to monitor the
fate of electron-dense nanoparticles in the organism. The
method of choice for evaluation is a quantitative morpho-
metric approach, which is by far preferable over qualita-
tive spotting images, which may lead to a wrong
interpretation. In addition, it is strongly recommended to
search for adequate alternate labeling techniques, which
may not be obvious at the first glance but would still pro-
vide a feasible option, for example use of confocal micro-
scopy with fluorescently labeled nanoparticles.
• Chemical analysis may be possible
If the matrix of the nanoparticle provides a characteristic
chemical element or compound, chemical analysis of this
characteristic provides another strong alternative to track
the fate of nanoparticles. Importantly, contamination and
possible endogenous background levels require careful
distinction as well as the determination of the lower level
of sensitivity of the analytical approach.
4.3.2.4 Genomics and Proteomics
Nanomaterials distributing to different tissues of the body
following deposition in the respiratory tract can poten-
tially affect multiple cellular functions, and it will be dif-
ficult to determine with conventional assays what changes
and adverse effects may have occurred. Use of genomic
and proteomic analyses should be considered, the former
providing information about specific mechanisms at the
molecular level (e.g., oxidative stress) and the latter link-
ing this to the expression of proteins resulting in effects at
the cellular and tissue level. Results from such analyses are
needed to help in the interpretation of responses. Analysis
of the results of these assays requires the input of bioinfor-
matics which will help in the interpretation of elicited
responses. Together, genomic and proteomic studies rep-
resent an effective strategy combining hypothesis-forming
and hypothesis-driven research which is needed in the
assessment of nanoparticle risks within the framework of
a multidisciplinary team approach.
4.3.2.5 Effects on the Reproductive system, Placenta, and Fetus
The studies to assess Tier 2 reproductive effects following
pulmonary exposures to nanoparticles should follow pro-
tocols similar to the OECD Guideline 422 for Testing of
Chemicals (Combined Repeated Dose Toxicity Study with
the Reproduction/ Developmental Toxicity Screening Test
– adopted 3-22-1996). The test substance should be
administered in gradual doses to several groups of male
and female rats. Males should be dosed for a minimum of
4 weeks (which includes a minimum of 2 weeks prior to
mating during the mating period and approximately 2
weeks post mating). Given the limited pre-mating dosing
period in males, fertility may not be a particularly sensi-
tive indicator of testicular toxicity and should be concom-
itant with a detailed histopathological analysis of the
male gonads to assess impact on fertility and
spermatogenesis.
Females should be dosed throughout the study – includ-
ing 2 weeks prior to mating (with the objective of covering
a minimum of 2 estrus cycles), the variable time to con-
ception, the duration of pregnancy, and a minimum of 4
days after delivery, up to and including the day before the
scheduled sacrifice. The duration of gestation should be
recorded and is calculated from day 0 of pregnancy. Each
litter should be examined as soon as possible after deliv-
ery to establish the number and sex of pups, stillbirths,
live births, runts (pups that are significantly smaller than
corresponding control pups), and the presence of gross
abnormalities.
Live pups should be counted and sexed and litters
weighed within 24 hours of parturition (day 0 or 1 post-
partum) and on day 4 post-partum. In addition to the
observations on parent animals, any abnormal behavior
of the offspring should be recorded.
4.3.3 Oral Exposure – Tier 1
It is possible that during the life of a nanomaterial (pro-
duction, application, disposal, etc) it may appear in the
water supply or be inadvertently ingested. If this is a con-
cern, the effects of oral exposure to the nanomaterial
should be investigated. Exposure should be by a single
gavage at a dose which would represent the worse case
human exposure. As with pulmonary exposure, for oral
exposure the physical and chemical properties of the test
material should be characterized in the form delivered to
the test animal. Rats or mice are the recommended model
system. There is no preference concerning gender for such
studies. The feces should be collected for four days post-Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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exposure, and the amount of nanomaterial eliminated vs.
retained should be determined. Particularly GALT,
mesenteric lymph nodes and liver should be analyzed for
the presence of nanoparticles. If absorption of the nano-
material from the gastrointestinal tract is near zero, then
the systemic effects of oral exposure to that nanomaterial
need not be evaluated. However, if significant absorption
of the nanomaterial is evident, evaluation of systemic tox-
icity is recommended using histology and functional
assays as described for the various organ systems after pul-
monary exposure.
4.3.4 Injection – Tier 1
Some nanomaterials are being evaluated as drug delivery
systems. In such a case, the potential toxicity of this
nanomaterial after injection should be evaluated. Rats or
mice are the recommended model system. There is no
preference concerning gender for these studies. If possible,
a tagged nanoparticle should be injected and its distribu-
tion to various organs (liver, spleen, heart, bone marrow,
kidney, and lung) and elimination in the feces should be
monitored for a week post-exposure. Histology and func-
tional assays (e.g., mitochondrial function) of the various
organ systems should be implemented as described fol-
lowing pulmonary exposure (Section 4.3.1.4).
4.3.5 Skin Exposure – Tier 1
For skin absorption of nanomaterials, the most appropri-
ate animal model should be used. Rats are most common
but rabbits, guinea pigs and pigs are also used to assess
toxicity and irritation. The rat and pig are recommended
as the animal of choice. The rat being small and already
having an established database in the field of toxicology
by other routes of exposure could be used because the
amount of nanomaterials needed would be less for this
small species. Frequently, the domestic pig is utilized in
absorption studies because the skin is anatomically, phys-
iologically and biochemically similar to that of humans.
Twenty-four hours prior to dosing with nanomaterials,
the area (10% of the body surface) on the back should be
clipped to remove hair. Three doses at log intervals (mg/
cm2) plus controls (vehicle, no material controls and a
positive control) should be applied to both normal skin
and abraded skin to mimic how humans are exposed. The
material should be applied in an occluded fashion
because nanomaterials, unlike many chemicals, will not
be absorbed into the skin immediately. The occlusion
device (site protection) used to prevent the nanomaterial
from falling off should be attached to the surface of the
skin by non-irritating tape. At least 4–6 animals per
group/ dose plus controls and vehicle controls should be
utilized over the duration of 24 hrs. At 0.5, 1, 2, 4, 8, and
24 hrs, the treatment sites should be scored for erythema
and edema using the Draize test scores. Skin biopsies
should be taken for transmission electron microscopy that
would identify cellular changes as well as localize the pen-
etrated particles within the skin. Light microscopy could
be utilized to assess the morphological alterations that
could occur due to the acute toxicity of the nanomaterials
but this will not detect nanomaterial localization. For
repeated exposures, nanomaterials should be applied
daily for 5 or 7 days and could continue until 28 days.
This could depend on the type and the amount of nano-
materials that are available. If a 28 day study is planned,
then daily clinical observations should be conducted. At
termination, hematology, clinical chemistry, evaluation
of local lymph nodes and an immunotoxicology battery
of tests should be performed. Standard full necropsy exam
(liver, kidney, etc) should also be conducted [183,184].
The specific goal of the study, dermal absorption or irrita-
tion, will dictate the specific study design (e.g. duration of
study, samples collected).
4.3.6 Research Gaps
Significant research gaps exist; the first four included in
the following list pertain to general informational needs
on production, use, and exposure to nanomaterials that
would be helpful in the design of toxicity test.
1. What is being made and in what quantities in the nan-
otechnology industry?
2. What exposure levels are likely in the workplace?
3. What is/are the likely route(s) of exposure?
4. What are occupational vs. environmental exposures?
5. Radio-labeled particles are needed for investigation of
deposition, translocation, and biopersistence. This
requires specific lab that can work with and detect labeled
materials; labeling not feasible for many materials.
6. A source of reference nanomaterials should be available
to researchers.
4.3.7 Recommendations
1. Studies involving in vitro (non-cellular and cellular),
pulmonary, oral, injection and dermal exposure are rec-
ommended in Tier 1 testing.
2. It is essential that exposures in animal models be rele-
vant to human exposures, when known, for production,
use, and disposal.
3. It is recommended that exposure route be relevant to
anticipated human exposures for production, use, and
disposal.Particle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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4. It is recommended that the test material be fully charac-
terized, preferably as delivered to the animal.
5. Following pulmonary exposure, recommended end-
points to be measured include organ-specific markers of
inflammation, oxidant stress and cell proliferation (e.g.,
mitochondrial) and histopathology in the lung as well as
measurement of damage to non-pulmonary organs.
6. Studies involving a) use of susceptible models, b) mul-
tiple exposures, c) evaluation of deposition, translocation
and biopersistence, d) reproductive effects, and e) mecha-
nistic genomic and proteomic techniques may be consid-
ered for Tier 2 testing.
5.0 Conclusion
Engineered nanomaterials presenting a potential risk to
human health include those capable of entering the body
and exhibiting a biological activity that is associated with
their nanostructure. Nanomaterial-based products such as
nanocomposites, surface coatings and electronic circuits
are unlikely to present a direct risk as exposure potential
will be low to negligible. Nanomaterials that are most
likely to present a health risk are nanoparticles, agglomer-
ates of nanoparticles, and particles of nanostructured
material (where the nanostructure determines behavior).
In each of these cases, exposure potential exists for mate-
rials in air and in liquid suspensions or slurries.
Recognizing the early stage of understanding of the poten-
tial toxicity of nanomaterials and that little knowledge
exists regarding specific nanomaterial characteristics
which may be indicators of toxicity, the elements of a
screening strategy outlined in this document include a sig-
nificant research component. The range and extent of rec-
ommended testing reflect this developing state of
knowledge. The elements of a screening strategy are clear,
but the detailed approach will evolve and become more
focused and selective as the results of these early-stage
screening/research studies become available. A more thor-
ough discussion of the 'elements' presented and the devel-
opment of a more robust and detailed strategy will only
be possible as knowledge increases. Elements of a nanoto-
xicity testing strategy which have been detailed in previ-
ous sections are summarized below.
Physicochemical Characterization
Appropriate physicochemical characterization of nano-
materials used in toxicity screening tests is essential, if
data are to be interpreted in relation to the material prop-
erties, inter-comparisons between different studies carried
out, and conclusions drawn regarding hazard. The
dependence of nanomaterial behavior on physical and
chemical properties places stringent requirements on
physicochemical characterization and includes assessing a
range of properties, including particle size distribution,
agglomeration state, shape, crystal structure, chemical
composition, surface area, surface chemistry, surface
charge and porosity. Precise requirements will differ for in
vivo and in vitro studies, and according to the material
delivery route or method. In addition, characterizing
human exposures introduces a third set of requirements.
A wide range of analytical methods are available that are
applicable to nanomaterials, and multidisciplinary col-
laborations are encouraged to ensure appropriate meth-
ods are adopted. Particular consideration should be given
to the use of Transmission Electron Microscopy, which in
many cases can be considered the gold standard of nano-
particle characterization. In addition, information on
nanomaterial production, preparation, storage, heteroge-
neity and agglomeration state should be recorded in all
cases. Characterization of nanomaterials after administra-
tion in vitro or in vivo is considered the ideal in screening
studies, although it currently presents significant analyti-
cal challenges. Characterization of the material as admin-
istered is therefore recommended for most screening tests.
Characterization of the nanomaterial solely as produced
or supplied is only considered appropriate where the pre-
vious two approaches are not viable. In all screening stud-
ies, dose should be evaluated against appropriate metrics.
The three principal physical metrics of interest are mass,
surface area and number concentration of particles: given
current uncertainty over the relevance of each, it is
important that all three are measured or derivable in any
given study.
In Vitro Testing Methods
In vitro tests of toxicity yield data rapidly and can provide
important insights and confirmations of the mechanism
of in vivo effects. We recommend that a wide range of in
vitro tests be applied to the key research questions relating
to the potential hazard associated with nanoparticles
exposure. A wide range of in vitro approaches exist that can
be matched to specific questions relating to different
aspects of nanoparticles toxicity. Non-cellular tests can
provide information on aspects such as biopersistence,
free radical generation by particle surfaces and activation
of humoral systems such as the complement system; com-
putational toxicology methods may also be useful. Cell-
based systems can comprise cell lines and freshly derived
primary cells in monocultures or co-cultures. Organ cul-
tures and heart/lung preparations are also potentially use-
ful for studying nanoparticles effects and translocation.
We recommend that the in vitro tests should reflect the dif-
ferent portals of entry and target organs that nanoparticles
could impact and these include lung, skin, mucosal mem-
branes, endothelium, blood, spleen, liver, nervous sys-
tem, and heart. As always, care should be taken in
interpreting data obtained from in vitro systems because ofParticle and Fibre Toxicology 2005, 2:8 http://www.particleandfibretoxicology.com/content/2/1/8
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the high doses normally used in vitro and the impact of a
bolus effect. There should be inclusion of appropriate
benchmark particles to contextualize the results of in vitro
assays. We recommend vigilance for artifactual effects
peculiar to nanoparticles caused by their large adsorptive
surface which can deplete cell products or assay constitu-
ents and thereby confound assay results. In addition to
the utilization of existing test systems we suggest that new
assays may be developed, for example to study transit of
nanoparticles across cell layers.
In Vivo Testing Methods
For in vivo testing of nanomaterials, two tiers of studies are
discussed. Tier 1 studies would involve pulmonary, oral,
injection, and dermal exposure as would be relevant to
the human exposure(s) of concern. A critical initial step in
in vivo testing is full characterization of the test material.
Endpoints of concern for pulmonary exposure involve
organic-specific markers of inflammation, oxidant stress,
and cell proliferation and histopathology in the lung as
well as measurement of damage to non-pulmonary
organs. Tier 2 pulmonary exposure studies are recom-
mended but not mandated. These studies would provide
useful information for a complete risk assessment of a
nanomaterial. Tier 2 studies include: 1) use of susceptible
models, 2) effects of multiple exposures, 3) deposition,
translocation and biopersistence studies, 4) evaluation of
reproductive effects, and 5) mechanistic studies employ-
ing genomic and proteomic techniques.
The testing strategy for in vivo studies would be of greatest
value for hazard identification and risk assessment if
exposure dose, route of exposure, and particle characteris-
tics closely modeled those of human exposure. Therefore,
an understanding of the life cycle of a given nanomaterial,
i.e., exposure during production, upon use, and environ-
mentally, is a critical research need.
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